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Abstract
Southeast Asia is an epicenter of multidrug-resistant Plasmodium falciparum strains.
Selective pressures on the subcontinent have recurrently produced several allelic variants
of parasite drug resistance genes, including the P. falciparum chloroquine resistance trans-
porter (pfcrt). Despite significant reductions in the deployment of the 4-aminoquinoline
drug chloroquine (CQ), which selected for the mutant pfcrt alleles that halted CQ efficacy
decades ago, the parasite pfcrt locus is continuously evolving. This is highlighted by the
presence of a highly mutated allele, Cam734 pfcrt, which has acquired the singular ability
to confer parasite CQ resistance without an associated fitness cost. Here, we used pfcrt-
specific zinc-finger nucleases to genetically dissect this allele in the pathogenic setting of
asexual blood-stage infection. Comparative analysis of drug resistance and growth profiles
of recombinant parasites that express Cam734 or variants thereof, Dd2 (the most common
Southeast Asian variant), or wild-type pfcrt, revealed previously unknown roles for PfCRT
mutations in modulating parasite susceptibility to multiple antimalarial agents. These
results were generated in the GC03 strain, used in multiple earlier pfcrt studies, and might
differ in natural isolates harboring this allele. Results presented herein show that Cam734-
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mediated CQ resistance is dependent on the rare A144F mutation that has not been
observed beyond Southeast Asia, and reveal distinct impacts of this and other Cam734-
specific mutations on CQ resistance and parasite growth rates. Biochemical assays
revealed a broad impact of mutant PfCRT isoforms on parasite metabolism, including
nucleoside triphosphate levels, hemoglobin catabolism and disposition of heme, as well as
digestive vacuole volume and pH. Results from our study provide new insights into the
complex molecular basis and physiological impact of PfCRT-mediated antimalarial drug
resistance, and inform ongoing efforts to characterize novel pfcrt alleles that can undermine
the efficacy of first-line antimalarial drug regimens.
Author Summary
Point mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT)
earlier thwarted the clinical efficacyof chloroquine, the former gold standard, and consti-
tute a major determinant of parasite susceptibility to antimalarial drugs. Recently, we
reported that the highly mutated Cambodian PfCRT isoform Cam734 is fitness-neutral in
terms of parasite growth, unlike other less fit isoforms such as Dd2 that are outcompeted
by wild-type parasites in the absence of CQ pressure. Using pfcrt-specific zinc-finger nucle-
ases to genetically dissect the Cam734 allele, we report that its unique constituent mutations
directly contribute to CQ resistance and collectively offset fitness costs associated with
intermediate mutational steps. We also report that these mutations can contribute to resis-
tance or increased sensitivity to multiple first-line partner drugs. Using isogenic parasite
lines, we provide evidence of changes in parasite metabolism associated with the Cam734
allele compared to Dd2.We also observe a close correlation betweenCQ inhibition of
hemozoin formation and parasite growth, and provide evidence that Cam734 PfCRT can
modulate drug potency depending on its membrane electrochemical gradient. Our data
highlight the capacity of PfCRT to evolve new states of antimalarial drug resistance and to
offset associated fitness costs through its impact on parasite physiology and hemoglobin
catabolism.
Introduction
Human malaria remains a leading global health scourge in part due to multidrug resistance
mechanisms evolved by Plasmodium falciparum, the protozoan species responsible for the
most severe forms of disease [1]. Artemisinin-basedcombination therapies (ACTs) are the cur-
rent first-line means of controlling pathogenic asexual blood-stage infections, including ones
dominated with drug-resistant strains that arose during previous selective sweeps resulting
from the global use of chloroquine (CQ) and sulfadoxine-pyrimethamine [2–4]. The 4-amino-
quinoline compound CQwas especially pivotal earlier in reducing mortality rates [5]. How-
ever, the multi-focal emergence and spread of CQ resistance (CQR) contributed to stalled
control measures and substantial increases in malaria-associated hospitalizations and deaths
[6]. Nevertheless, owing to its safety, affordability, and established efficacy against non-resis-
tant parasites, CQ continues to be deployed in regions that are free of CQR or that harbor CQ-
sensitive P. vivax [7]. Interestingly, studies of infections with CQ-resistant P. falciparum strains
in Guinea-Bissau recently revealed a ~5–fold increase in CQ efficacy upon doubling the stan-
dard dose in children aged<5 years, the age demographic at highest risk for malaria mortality
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[8]. These findings coincide with renewed efforts to delineate the molecular basis of resistance
to antimalarials bearing the hallmark CQ-type quinoline moiety [9].
Genetic linkage and allelic replacement studies have previously identified pfcrt variants as
the primary determinant of CQR [10,11]. These findings are supported by evidence of direc-
tional selection for mutant pfcrt alleles in P. falciparum parasite populations subjected to exten-
sive CQ pressure [12]. A secondary, strain-dependent contribution to CQR has also been
noted for the P. falciparum multidrug resistance 1 (pfmdr1) gene [13–15]. Among CQ-resistant
field isolates, PfCRT isoforms are comprised of geographically distinct clusters of single-nucle-
otide polymorphisms (SNPs), namely K76T and 3 to 8 additional point mutations. PfCRT
K76T is a critical, albeit insufficient, determinant of parasite in vitro CQR [16]. This mutation
also predicts in vivo CQ treatment failure with high sensitivity but lower specificity [17]. At the
cellular level, PfCRT is a multi-pass transporter embedded in the intra-erythrocyticparasite’s
digestive vacuole (DV) membrane, with enigmatic functions that may include transport of
ions and/or peptides [18–21]. In the absence of PfCRT structural information, mutational
approaches have guided studies into the effect of specific PfCRT mutations on drug transport
and parasite growth [16,22–24].
Point mutations in PfCRT have also been associated with altered parasite susceptibility to
ACT component drugs, namely artemisinins and their partner drugs (including amodiaquine,
lumefantrine, and piperaquine) [25–29]. This is of particular relevance given reports of emerg-
ing clinical resistance to these first-line agents [30,31]. To various degrees, these compounds
interfere with or are otherwise impacted by parasite-mediated catabolism of host hemoglobin
(Hb), which supplies parasites with amino acids and helps maintain intracellular osmolarity
[32–35]. This catabolic process produces ferriprotoporphyrin IX heme, which in its reactive
free form can exert lethal oxidative damage to the parasite [36]. For quinoline-based antimalar-
ials, drug-heme interactions in the DV cause toxicity by preventing incorporation of ferriproto-
porphyrin IX heme dimers (β-hematin) into the non-reactive hemozoin (Hz) crystals that
account for>95% of total heme [37,38]. Consistent with this inhibition of β-hematin minerali-
zation and detoxification, CQ treatment of drug-sensitiveD10 parasites was recently observed
by transmission electronmicroscopy to disrupt the highly ordered fringe pattern of Hz crystals
[32].
Cell fractionationmethods in P. falciparum D10 parasites have further demonstrated that,
upon CQ treatment, the proportion of total heme present as Hz significantly diminishes,
whereas the proportion corresponding to free heme increases [32]. These responses are dose-
dependent and inversely proportional to parasite survival [32]. As a weak base and lipophilic
drug, CQ traverses multiple lipid bilayers and accumulates as CQ2H+ up to a thousand-fold in
the acidic DV, where it binds hematin, hemozoin, or both [39]. CQR-promoting PfCRT iso-
forms appear to efficiently transport CQ out of the DV, consequently restricting CQ-heme
contacts and allowingHz formation to proceed [7,21]. Of note, the mutational status of pfcrt
can also impact DV volume and pH, both of which influenceHz formation kinetics [40].
Interestingly, recent metabolomic analyses of CQ-resistant versus CQ-sensitive P. falcipa-
rum strains detected a link betweenmutant pfcrt-mediatedCQR and the elevated accumulation
of peptides derived fromHb digestion [41]. Given the reduced growth of CQ-resistant parasites
(expressing the Dd2 or 7G8 mutant pfcrt alleles) relative to recombinant isogenic parasites
encodingwild-type pfcrt, defectiveHb degradation was postulated as a cellular basis for the
reduced fitness associated with mutant pfcrt [41]. Reduced fitness of these mutant alleles was
confirmed in in vitro cell culture studies [41,42] and was observed at a population level in
Africa, where the removal of CQ pressure led to the attrition of mutant pfcrt-expressing para-
sites in favor of wild-type, CQ-sensitive strains [43,44].
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A pathogen’s fitness refers to its capacity to support infection and generate new progeny. For
P. falciparum parasites, fitness is influenced in part by the rate of growth of pathogenic asexual
blood-stage parasites, selective forces exerted by drug pressure, mosquito-human transmission,
and selectionwithin the mosquito vector [41,44,45]. In general, these factors are impaired in
parasites expressing mutant, CQR-associated PfCRT isoforms [7,46]. To date, over 50 distinct
PfCRT haplotypes have been reported [22]. Of these, the Asian haplotype Dd2 (M74I/N75E/
K76T/A220S/Q271E/N326S/I356T/R371I) and the South American/Western Pacific haplotype
7G8 (C72S/K76T/A220S/N326D/I356L) account for a large proportion of global mutant types,
with additional isoforms harboring four or more SNPs and resembling the PfCRT haplotypes
Dd2 or 7G8 (notably the six-SNP African variant GB4 or the four-SNP South American variant
Ecu1110 respectively) [7]. Recent modeling in P. falciparum suggests that pfcrt evolution
occurred via punctuated periods of mutation that were too brief to allow fixation of partially
mutated alleles (i.e. bearing 1 to 3 SNPs), shedding light on physiologic constraints that explain
the rarity of mutant pfcrt emergence in the field [16]. Intriguingly, studies from Cambodia, an
epicenter of multidrug resistance in P. falciparum, also revealed a highly polymorphic CQR-
conferring pfcrt allele, Cam734 [47]. This allele encodes nine mutations (see Table 1), five of
which (N75D, A144F, L148I, I194T, T333S) are not found in the predominant Southeast Asian
CQ-resistant pfcrt allele, Dd2 [22]. After Dd2, Cam734 pfcrt represents the secondmost preva-
lent allele in Southeast Asia [27]. Unlike other CQR-associated isoforms such as Dd2, the
Cam734 allele has been found to be fitness-neutral in that it supports parasite growth compara-
ble to recombinant pfcrt-edited parasites (engineered on the same strain, and referred to as iso-
genic) that encode the CQ-sensitive, wild-type pfcrt allele [42].
This unique Cam734 PfCRT isoform presents an opportunity to explore P. falciparum
genetic determinants that concurrently confer drug resistance and fully neutralize fitness costs,
a unique feature not associated with other mutant PfCRT variants. Herein, we leveraged drug
resistance versus growth profiling of isogenic, pfcrt-modifiedasexual blood-stage parasites.
These studies were combined with biochemical approaches—including metabolomic, heme
fractionation, and heterologous expression studies—in order to address the following ques-
tions: (1) To what extent do the mutations unique to Cam734 PfCRT directly impact parasite
resistance to clinically employed antimalarials? (2) Which mutations are compensatory and
thus serve to preserve PfCRT function? and (3) Mechanistically, how does mutant Cam734
PfCRT confer CQR without an accompanying fitness cost? Results provided herein broaden
our present understanding of the mechanistic basis of CQR and inform field efforts that evalu-
ate pfcrt genotypes as a tool to predict the drug susceptibility status of clinical isolates.
Results
Generation of isogenic parasites encoding full-length or back-mutated
Cam734 pfcrt alleles
To dissect the contributions of the rare mutations comprising Cam734 PfCRT to parasite drug
resistance and fitness, we utilized a recently established [48] gene-editing approach (S1 Fig)
with pfcrt-specific zinc-finger nucleases (ZFNs). Starting with the GC03 strain, a CQ-sensitive
progeny of the HB3×Dd2 genetic cross [49], we engineered isogenic parasites encoding full-
length Cam734 pfcrt (GC03Cam734; the PfCRT haplotype of recombinant lines is listed in super-
script) as well as partial Cam734-like isoforms containing “back-to-wild-type”mutations at
PfCRT residues 75, 144, 148, 194, and 333 (see Table 1). Our parasite panel also included the
GC03Dd2 and GC03GC03 lines, which encode the mutant Dd2 (CQ-resistant) and wild-type
GC03 (CQ-sensitive) haplotypes, respectively and which were similarly engineered using ZFN-
based editing (see Table 1). This ZFN approach enables the expression of only full-length pfcrt,
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and is thus a significant improvement over the prior allelic exchange method [11] that in addi-
tion to expressing full-length pfcrt also generated truncated fragments that created the possibil-
ity of internal recombination events. We note that the host GC03 strain has been used in
multiple prior pfcrt allelic exchange and gene editing studies [11,16,42,48,50], providing exten-
sive background data on parasite drug susceptibilities, transport properties, transcriptional
changes, drug-heme interactions and metabolomics [41,51–59]. For each recombinant line,
two independent clones were selected, and pfcrt sequence integrity was verified using sequenc-
ing primers listed in S1 Table. Recombinant parasite design and validation, including PCR-
based confirmation of the recombinant locus, cDNA sequencing that showed error-free edit-
ing, andWestern blot analysis confirming equivalent expression, is further detailed in S1 Fig
and SupplementaryMaterials andMethods.
Cam734 pfcrt-defining mutations impact parasite responses to
chloroquine
We examined the roles of Cam734 PfCRT-constituent mutations in mediating CQR by assess-
ing the responses of recombinant, pfcrt-modifiedparasites to CQ and its clinically relevant
metabolite, monodesethyl-CQ (md-CQ).Md-CQ was included in our analysis as it shows a
greater distinction betweenCQ-sensitive and CQ-resistant lines and may have been the pri-
mary evolutionary selective agent [11,16]. For all drug assays, genetically unmodifiedDd2 and
GC03 parasites were included as reference lines (see Table 1). Using 72 h flow cytometry-based
drug susceptibility assays, we determined antimalarial drug concentrations that result in 50%
(IC50) and 90% (IC90) inhibition of parasite proliferation (S2 Table). Both values have earlier
proven informative in defining CQ susceptibility phenotypes, particularly in cases of low-level
resistance or tolerance [50]. Statistical comparisons were performed against GC03Cam734 para-
sites, which express the full-lengthCam734 pfcrt allele. In our analysis, recombinant GC03 par-
asites encoding the major Southeast Asian pfcrt variants Cam734 and Dd2 conferredmoderate
(~5-fold and ~14-fold) and high-level (~26-fold and ~43-fold) increases in CQ and md-CQ
IC50 values, respectively, when compared to CQ-sensitive GC03GC03 parasites (S2 Table). This
is consistent with earlier P. falciparum drug susceptibility studies [42].
CQ (Fig 1A; S2 Table) and md-CQ (Fig 1B; S2 Table) susceptibility profiles revealed signifi-
cant roles for multiple Cam734 PfCRT-defining mutations in conferring CQR. Among these,
Table 1. PfCRT status of lines employed in this study.
PfCRT residue
Parasite Line PfCRT haplotype Rec. 74 75 76 144 148 194 220 271 326 333 356 371
GC03Cam734 Cam734 Yes I D T F I T S E N S I R
GC03Cam734 D75N Cam734 D75N Yes I N T F I T S E N S I R
GC03Cam734 F144A Cam734 F144A Yes I D T A I T S E N S I R
GC03Cam734 I148L Cam734 I148L Yes I D T F L T S E N S I R
GC03Cam734 T194I Cam734 T194I Yes I D T F I I S E N S I R
GC03Cam734 S333T Cam734 S333T Yes I D T F I T S E N T I R
GC03Dd2 Dd2 Yes I E T A L I S E S T T I
Dd2 Dd2 No I E T A L I S E S T T I
GC03GC03 GC03 (wild-type) Yes M N K A L I A Q N T I R
GC03 GC03 (wild-type) No M N K A L I A Q N T I R
Dark gray shading denotes mutations specific to Cam734. Light gray shading denotes mutations present in Dd2, some of which are shared with Cam734.
PfCRT haplotypes Cam734 F144A and Cam738 are equivalent. Rec., recombinant.
doi:10.1371/journal.ppat.1005976.t001
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Fig 1. Drug resistance profiles of pfcrt-modified and reference parasite lines. (A) Parasite chloroquine
(CQ) responses and verapamil (VP) reversibility of CQ resistance. Briefly, flow cytometry was used to
assess parasitemias and quantify the corresponding drug concentration-dependent inhibition following 72 h
exposure to the indicated antimalarial drugs. Bar graphs correspond to mean ± SEM IC50 or response
modification index (RMI) values. IC50 values correspond to the drug concentrations that produced 50%
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PfCRT A144F was indispensable for CQ and md-CQ resistance (compare GC03Cam734 with
the GC03Cam734 F144A line). Indeed, removal of this mutation restored complete to near-com-
plete sensitivity to CQ and md-CQ respectively, at IC50 and IC90 levels (S2 Table). The
Cam734 F144A PfCRT haplotype (see Table 1) is equivalent to Cam738 PfCRT, which, like
Cam734, was initially documented in Cambodia but, in contrast, did not achieve wide regional
spread [47]. Notably, although the Cam734 F144A haplotype harbors K76T and seven addi-
tional mutations, its mutational configuration is nevertheless insufficient for CQR (see Fig 1A
and S2 Table). This underscores the notion of K76T as an insufficient predictor of CQR status
and supports the fact that CQ resistance or susceptibility can depend on additional PfCRT sub-
stitutions (e.g. C101F, L272F, C350R, or in this case A144F), even when K76T is present
[22,60–62].
Our analysis identified additional contributory roles for PfCRT mutations N75D, L148I,
and T333S in conferring parasite resistance to CQ (Fig 1A; S2 Table) and md-CQ (Fig 1B; S2
Table), as parasite lines encoding back-mutations at each of the corresponding PfCRT residues
demonstrated significant reductions in resistance (range of 1.5 to 3.7-fold reductions in CQ or
md-CQ IC50 values for GC03Cam734 D75N, GC03Cam734 I148L, and GC03Cam734 S333T as com-
pared to GC03Cam734 parasites). Thus, to various degrees, N75D, A144F, L148I, and T333S
directly contribute to CQR and are not merely compensatory in nature in terms of restoring
function or fitness to mutant PfCRT isoforms. Only the I194T mutation was found to not sig-
nificantly contribute to CQR.
A definingmolecular feature of P. falciparum CQR is resistance reversal by the calcium
channel blocker verapamil (VP) [52]. The extent to which VP modifies CQR, referred to as the
CQ response modification index (RMI), is PfCRT isoform-specific and is calculated by dividing
the IC50 value for CQ in the presence of 0.8 μM VP by the IC50 value for CQ alone [63]. Our
CQR reversibility results are depicted in Fig 1A and S3 Table. Consistent with previous studies
[42], isogenic parasites expressing PfCRT variants Cam734 (GC03Cam734) and Dd2 (GC03Dd2)
exhibited moderate and high-level CQR reversibility (2.4-fold and 8.1-fold reductions in the
CQ RMI, respectively, versus the GC03GC03 line that showed no CQR reversibility). Among
the recombinant lines encoding partial, back-to-wild-typeCam734 PfCRT haplotypes,
GC03Cam734 D75N and GC03Cam734 I148L parasites exhibited statistically significant increases in
CQ RMI values as compared to GC03Cam734 parasites, highlighting critical roles for mutations
N75D and L148I in the VP reversibility effect. These findings uncover a novel role for PfCRT
residue 148 in mediating VP reversal of CQR and align with previous studies that implicate an
important role for mutations at residue 75 in mediating this reversal phenotype [42,64].
Cam734 pfcrt-defining mutations impact parasite responses to clinically
important antimalarials
PfCRT variants can modulate parasite susceptibility to a host of antimalarials beyond CQ [7].
We consequently assessed the effects of Cam734 PfCRT-constituent mutations on parasite
responses to various clinically employed antimalarials (Fig 1 and S2 Fig). Our drug panel
inhibition of parasite growth. The RMI of CQ IC50 is equivalent to (IC50 for CQ + VP) (IC50 for CQ only), as
detailed in Materials and Methods. (B) Parasite responses to monodesethyl (md)-chloroquine, md-
amodiaquine, quinine, and piperaquine. Bar graphs indicate mean ± SEM IC50 values. Results encompass 3
to 12 independent assays conducted in duplicate. Statistical differences were determined via non-parametric
Mann-Whitney U tests, using the mean IC50 value of Cam734 pfcrt-expressing GC03Cam734 parasites as the
comparator. CQ susceptibility and CQ RMI data are summarized along with corresponding statistical tests in
S2 and S3 Tables, respectively. IC90 values and Hill slopes are also presented in S2 Table. *P<0.05;
**P<0.01; ***P<0.001. ****P<0.0001.
doi:10.1371/journal.ppat.1005976.g001
Molecular Analysis of the Evolution of Fitness Cost-Neutral Mutant PfCRT
PLOS Pathogens | DOI:10.1371/journal.ppat.1005976 November 10, 2016 7 / 29
consisted of the following: (1) ACT partner drugs, including monodesethyl-amodiaquine (md-
AQ, the active metabolite of AQ), lumefantrine (LUM), piperaquine (PPQ), and pyronaridine
(PND); (2) the ACT artemisinin derivative artesunate (AS); and (3) quinine (QN), a second-line
agent used to treat severemalaria. In keeping with known cross-resistance relationships between
CQ and AQ [7], we observed significant reductions in md-AQ resistance (Fig 1B; S2 Table)
among parasites harboring reversions of Cam734 PfCRT mutations N75D, A144F, L148I, and
T333S (range of 1.4 to 4.0-fold reductions in md-AQ IC50 values for GC03Cam734 D75N,
GC03Cam734 F144A, GC03Cam734 I148L, and GC03Cam734 S333T as compared to GC03Cam734 para-
sites). Reversion of the PfCRT mutation A144F back to wild-type (compare GC03Cam734 with
GC03Cam734 F144A) was likewise associated with a significant (~1.6-fold) reduction in QN IC50
values (Fig 1B; S2 Table), emphasizing A144F as a critical determinant of parasite resistance
to multiple quinoline-type antimalarials.We further detected a modest (~1.5-fold), although
statistically significant, increase in PPQ IC50 for GC03Cam734 I148L parasites, as compared to
GC03Cam734 parasites. This highlights the capacity of PfCRT mutations to impact parasite PPQ
resistance, a rising problem in Southeast Asia with a presently unclear genetic basis [30,65,66].
As compared to wild-type (GC03) pfcrt, full-lengthCam734 sensitized parasites to the antima-
larial compounds LUM, AS, and PND, and this phenotype was not modulated by any of the
Cam734-constituent mutations studied herein (S2 Fig; S2 Table).
Cam734 pfcrt-defining mutations offset parasite fitness costs in vitro
Previous efforts to disrupt the pfcrt gene demonstrated that it is essential for survival of asexual
blood-stageP. falciparum parasites [67]. Furthermore, PfCRT mutations can be deleterious to
parasite growth [16,42], a measurable phenotype that serves as a proxy for fitness and reflects
parasite functional requirements [68]. To evaluate the contributions of Cam734-unique PfCRT
mutations to parasite growth, we used previously established co-culturemethods to derive rela-
tive growth estimates [16,69]. Co-cultures consisted of equal proportions of a pfcrt-modified
GFP-negative (GFP−) test line and a wild-type pfcrt-expressing GFP-positive (GFP+) reporter
line (seeMaterials and Methods). To assess the impact of a sub-therapeutic dose of CQ on par-
asite growth, experiments were performed in the absence or presence of 7.5 nM CQ (~0.5× CQ
IC50 of CQ-sensitive GC03GC03 parasites; see S2 Table). These co-cultures were monitored for
10 generations, with the GFP− proportion of the co-culture determined every 48 h generation
by flow cytometry (S3 Fig). As detailed inMaterials andMethods and SupplementaryMateri-
als andMethods, these data were used to derive the per-generation selection coefficient (s)
of each test line (Fig 2; S4 Table). This coefficient serves as a proxy for the degree of fitness of
a given parasite line, as compared to GC03Cam734 parasites, which encode the full-length
Cam734 pfcrt allele (s = 0, s>0, and s<0 indicate fitness levels equal, greater than, or less than
that of GC03Cam734 parasites).
As determined in our in vitro growth assays (Fig 2; S4 Table), the growth rate of parasites
encodingCam734 pfcrtwas markedly increased relative to isogenic parasites encodingmutant
Dd2 pfcrt (s = -0.25 for GC03Dd2 versus GC03Cam734) and was more comparable to growth of
parasites encodingwild-typeGC03 pfcrt (s = 0.06 for GC03GC03 versus GC03Cam734). These
findings agree with earlier studies of isogenic, pfcrt-modified lines constructed via an indepen-
dent allelic exchange strategy [42]. Remarkably, growth of GC03Cam734 parasites was signifi-
cantly enhanced (~1.2–fold; Fig 2; S4 Table) by the presence of a sub-lethal dose of CQ (7.5
nM), surpassing the growth rates of all other parasite lines, including those expressing GC03
pfcrt. Our results further demonstrate that the Cam734 PfCRT-constituent mutations N75D,
A144F, L148I, I194T, and T333S distinctly contribute to the growth of asexual blood-stage
parasites expressing full-lengthCam734 PfCRT, as the corresponding partial, back-mutant
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haplotypes conferred significantly decreased relative growth rates (with s values ranging from
-0.07 to -0.30 for GC03Cam734 D75N, GC03Cam734 F144A, GC03Cam734 I148L, GC03Cam734 T194I,
and GC03Cam734 S333T; see S4 Table).
Among the back-mutant parasites, the most deleterious growth was observed for parasites
expressing Cam734 I148L PfCRT, which was reminiscent of the growth phenotype of the Dd2
PfCRT isoform that is known to substantially impair parasite fitness (compare GC03Cam734 I148L
and GC03Dd2; Fig 2; S4 Table). Considering our dissection of the roles of Cam734 PfCRT muta-
tions in parasite CQ susceptibility and growth, our results suggest that PfCRT mutations N75D,
A144F, I148L, and S333T play dual roles, directly contributing to CQR and compensating for
associated fitness costs, whereas I194T has no impact on CQR and only helps improve growth.
Cam734 pfcrt affects hemoglobin processing and central carbon
metabolism
The catabolism of host-derivedHb is an essential parasite process that liberates two major
products: (1) free heme that is subsequently incorporated into crystallineHz; and (2) free Hb-
derived peptides that can contribute to the parasite’s nutrient pool [70]. Recent studies have
Fig 2. In vitro growth profiles of pfcrt-modified and reference parasite lines. Briefly, co-cultures initially
consisting of a 1:1 ratio of a GFP− test line and a GFP+ reporter line were monitored by flow cytometry each
48 h generation for 10 generations (see Materials and Methods and S3 Fig), and the per-generation selection
coefficient (s) for each test line was derived from parasite growth curves (see Supplementary Materials
and Methods). Bar graphs correspond to mean ± SEM s values for parasites subjected to no drug or 7.5 nM
chloroquine (CQ). A summary of s values and inter- and intra-strain statistical tests is provided in S4 Table.
doi:10.1371/journal.ppat.1005976.g002
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shown that peptides derived from either the α or β chains of Hb can accumulate up to 32–fold
within isogenic parasites expressing CQ-resistant Dd2 or 7G8 pfcrt alleles as compared to CQ-
sensitive (wild-type) pfcrt-expressing parasites [41]. The accumulation of Hb-derived peptides
in parasites expressing PfCRT Dd2 or 7G8 variants was linked to impaired Hb catabolism and
was proposed to be a causal determinant of their reduced fitness, as measured using in vitro
growth rates [41]. Given the unique capacity of mutant Cam734 PfCRT to neutralize fitness
costs that are typically associated with CQ-resistant PfCRT isoforms, we examined whether
Cam734 PfCRT mitigated the accumulation of Hb-derived peptides.
To test this, we measured endogenousmetabolite levels in isogenic lines encoding the CQ-
resistant pfcrt alleles Cam734 and Dd2 (GC03Cam734 and GC03Dd2). Briefly, red blood cells
(RBCs) harboring late-stage (~36–42 h) trophozoites were magnetically purified,metabolites
were extracted, and extracts were analyzed using established mass spectrometry-basedmetabo-
lomic methods [41]. Results are depicted in Fig 3 for compound classes and S4 Fig for individ-
ual metabolites. Metabolite signal intensities and z-scores are reported in S5 and S6 Tables,
respectively. Our results show that the CQ-resistant pfcrt alleles Cam734 and Dd2 accumulated
comparable levels of Hb-derived peptides (P = 0.33; see Fig 3 and S6 Table). Moreover, the
GC03Cam734 and GC03Dd2 peptide levels were significantly elevated relative to genetically
matched GC03GC03 parasites expressing the wild-type pfcrt [41]. Consequently, peptide accu-
mulation in these lines was not correlated with the observeddifferences in fitness between
Cam734 and Dd2.
To better understand the impact of the Cam734 allele, we conducted a more comprehensive
metabolic analysis of GC03Cam734 and GC03Dd2 parasites. This analysis revealed several distin-
guishingmetabolic phenotypes. Most significantly, ATP to ADP and ATP to AMP ratios were
significantly higher in GC03Cam734 compared to GC03Dd2 parasites (P = 0.0002 and P = 0.0001,
respectively; see Fig 3 and S6 Table). Low ATP to AMP ratios are a classic marker of lower cel-
lular energy and metabolic stress [71]; the relatively higher ratios seen in GC03Cam734 parasites
are consistent with their increased in vitro growth rate as compared with GC03Dd2 (see Fig 2).
GC03Cam734 parasites also exhibited significantly increased levels of glycolytic and tricarboxylic
acid (TCA) cycle-associatedmetabolites (P = 0.003 and P = 0.01, respectively; see Fig 3 and S6
Table). These elevated central carbonmetabolites may suggest that GC03Cam734 achieves its
altered energy state via a metabolic compensatorymechanism. Collectively, these findings indi-
cate that parasites encodingCam734 and Dd2 PfCRT both suffer from impaired parasite Hb
catabolism, but that the Cam734 PfCRT isoform compensates for this defect via a mechanism
that may involve alterations in central carbonmetabolism.
Distribution of heme species in isogenic pfcrt-modified parasites
CQ treatment of P. falciparum parasites affects their disposition of the different forms (“spe-
cies”) of heme, namely free heme, Hz, and Hb. In a dose-dependentmanner, CQ causes an
increase in toxic free heme, a decrease in the formation of chemically inert Hz crystals, and an
accompanying reduction in parasite survival [32]. To date, the profiles of heme fractions have
only been explored in CQ-sensitive (D10, NF54 and D6) parasites [72,73]. Given the central
role of pfcrt in dictating parasite responses to CQ, we examined the composition of heme spe-
cies in CQ-treated and untreated isogenic parasites encoding either the CQ-sensitive (wild-
type) pfcrt allele GC03 or the CQ-resistant (mutant) pfcrt alleles Cam734 or Dd2. Our heme
fractionation assay entailed treating synchronized early ring-stage parasites with CQ across a
range (0 to 3×) of its IC50 values for the different lines. After 32 h, trophozoite-stage parasites
were subjected to a series of cellular fractionation steps. The abundance of free heme, Hz and
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Hb was subsequently determined spectrophotometrically and reported both as a percentage of
total heme (Fig 4) and as an amount of heme iron (Fe) per cell (S5 Fig).
Our results demonstrate that parasite exposure to CQ caused a dose-dependent increase
in free heme for all pfcrt-modifiedparasite lines. Considering all CQ treatments, the highest
accumulation of free heme was observed in the CQ-sensitive GC03GC03 parasites, with
maximal mean free heme Fe concentrations of 19.3, 12.6, and 10.5 femtograms (fg) per cell
Fig 3. Metabolomic profiles of isogenic, mutant pfcrt-expressing parasites. Metabolite extracts derived from tightly synchronized
trophozoite-stage isogenic (GC03) parasites encoding either Dd2 or Cam734 pfcrt were analyzed by mass spectrometry. For each
metabolite class, individual metabolite signals were expressed as z-scores (detailed in Materials and Methods), allowing for direct
comparisons across distinct metabolite classes. Dashed lines represent lower (5%) and upper (95%) boundaries for the normal distribution,
as defined for GC03Dd2 (black) parasites. Metabolites were harvested on three independent occasions (n = 4 to 6 total replicates per parasite
strain). Compound class abbreviations, z-scores, and P values are presented in S6 Table.
doi:10.1371/journal.ppat.1005976.g003
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Fig 4. Distribution of heme species in control and chloroquine (CQ)-treated pfcrt-modified parasite lines. The percent of
total heme present as (A) free heme, (B) hemozoin (Hz), or (C) hemoglobin (Hb) was measured spectrophotometrically in
recombinant isogenic GC03 parasites expressing the wild-type (CQ-sensitive) GC03 pfcrt allele or mutant (CQ-resistant) Dd2 or
Cam734 pfcrt alleles. Prior to heme fractionation, synchronous parasites were exposed for 32 h to multiples of strain-specific CQ
IC50 values (1× IC50 values for GC03GC03, GC03Dd2, and GC03Cam734 in these experiments were 19.5 nM, 187 nM, and 90.9 nM,
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observed in GC03GC03, GC03Dd2, and GC03Cam734 parasites respectively (Fig 4A and S5A
Fig). The difference betweenGC03GC03 and GC03Cam734 parasites achieved statistical signifi-
cance (P = 0.02 by unpaired t test with Welch’s correction). Inversely correlating with free
heme profiles, Hz amounts showed comparable, CQ dose-dependent decreases (Fig 4B and
S5B Fig).
We note that GC03GC03 parasites showed a higher, statistically significant level of free heme
at baseline (i.e. in the absence of CQ) as compared to GC03Dd2 and GC03Cam734 parasites
(P = 0.004 and P = 0.0012, respectively, by unpaired t tests withWelch’s correction), although
the lowest level of Hz achieved in all three CQ-treated strains was comparable (Fig 4B).
Maximal free heme amounts in the presence of CQ even at very high concentrations were
also markedly lower in GC03Dd2 and GC03Cam734 parasites compared to the CQ-sensitive
GC03GC03 parasites (S5 Fig).
Several notable differences were also observed among the Hb profiles of pfcrt-modified lines
(Fig 4C and S5C Fig). First, GC03 parasites encodingwild-type (GC03) pfcrt exhibited lower
concentrations of Hb at baseline as compared to isogenic parasites expressing the mutant
pfcrt alleles Dd2 or Cam734 (mean amounts of 2.3, 3.7 and 6.3 Hb fg per cell respectively in
untreated samples; S5C Fig), with the difference between the GC03GC03 and GC03Cam734 lines
achieving statistical significance (P = 0.006 by unpaired t test withWelch’s correction). Consis-
tent with previous findings [32], CQ-sensitive GC03GC03 parasites (Fig 4C and S5C Fig)
showed a significant elevation in Hb species that did not occur until 2.5× CQ IC50. A compara-
ble accumulation in Hb starting at 2.5× CQ IC50 was observed for GC03Cam734 parasites, con-
trasting with the profile of GC03Dd2 parasites, which showed elevations in Hb amounts at a
lower (1×) CQ IC50 fold (Fig 4C and S5C Fig). The increase in Hb observed for GC03Dd2 para-
sites coincidedwith a statistically significant increase in free heme at 1× CQ IC50 (see Fig 4A).
This is consistent with previous studies of CQ-treated parasites, in which increases in undi-
gested Hb were found to follow significant increases in free heme [32].
For each pfcrt-modified line, we also compared the CQ dose dependence of free heme frac-
tions versus parasite growth (Fig 5). Interestingly, for each line, the free heme concentration
curve crossed the parasite growth curve at approximately the same mid-point (IC50 value),
indicating that the inverse relationship betweenCQ action on free heme levels and growth
inhibition that was previously observed for parasite lines encodingwild-type pfcrt [73] is pre-
served among lines encodingCQ-resistant pfcrt alleles. These data provide compelling evidence
that for both resistant and sensitive parasites, CQ-mediated growth inhibition results primarily
from this drug’s inhibition of Hz formation, which the parasite uses to detoxify reactive free
heme.
Cam734 PfCRT confers membrane potential-sensitive chloroquine
transport
A key feature of CQR in P. falciparum parasites is the ability of mutant PfCRT to efflux CQ
from the parasite DV, in turn reducing CQ access to heme. Measurement of drug transport is
experimentally challenging in Plasmodium parasites due to the presence of multiple mem-
brane-bound intracellular compartments. Accordingly, we evaluated CQ transport mediated
by Cam734 PfCRT using a recently optimized Saccharomyces cerevisiae galactose-inducible
respectively). Bar graphs indicate mean ± SEM percentage values for 5 to 10 independent replicates. For each parasite line,
values obtained for CQ-treated samples (gray bars) were compared against the untreated control (black bars), and statistical
significance was determined via unpaired t tests with Welch’s correction. Absolute amounts of heme species as a function of CQ
concentrations are depicted in S5 Fig. *P<0.05; **P<0.01; ***P<0.001. ****P<0.0001.
doi:10.1371/journal.ppat.1005976.g004
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PfCRT expression system [22]. Yeast-expressed PfCRT isoforms localize largely to the cell
membrane and mediate transport of CQ from the external medium (low pH, positive mem-
brane potential [C]) to the yeast cytosol (high pH, negative C), recapitulating the electro-
chemical gradient-driven transport of CQ from the parasite DV (low pH, positive C) to the
parasite cytosol (high pH, negative C) [74]. Of note, at baseline, the yeast cell membrane pos-
sesses a high ΔpH and a low Δψ. By increasing the pH of the external medium (pHexternal),
the cell membrane ΔpH can be experimentally lowered, yielding a compensatory potassium
channel-dependent increase in Δψ [74]. In this system, at higher Δψ, CQ transport by CQ-
resistant PfCRT isoforms is more pronounced as compared to the basal level of transport
mediated by the CQ-sensitive wild-typeGC03 PfCRT isoform [22,75]. Earlier studies have
validated that growth rates of PfCRT-expressing yeast serve as a useful proxy for CQ trans-
port [75].
Using quantitative growth rate analyses, we examined the effect of varying external pH (and
hence the Δψ) in yeast strains expressing PfCRT isoforms GC03, Cam734, the back-mutant
Cam734 F144A (chosen because this back mutation was the most effective at ablating CQ and
md-CQ resistance; see Fig 1), or Dd2 (see Table 1 for haplotypes). Growth was assessed in the
presence of 5 mMCQ, a concentration required for this drug to exert differential growth inhib-
itory activity on yeast strains expressing various PfCRT isoforms [22]. As a negative control,
we also included yeast harboring no PfCRT (vector control). To examine the effect of Δψ on
transport, we assessed growth over a range of pHexternal values (range of 7.20 [low Δψ] to 7.45
[high Δψ]; S6A Fig). Intriguingly, in low Δψ conditions, growth of yeast expressing Cam734
PfCRT was comparable to that of yeast expressing the CQ-sensitive GC03 PfCRT isoform (Fig
6). However, when the Δψ was clamped to higher values, Cam734 PfCRT conferred a CQR-
associated delayed growth phenotype that was intermediate to that of GC03 (wild-type) and
Dd2 PfCRT (Fig 6). Of note, the growth phenotype associated with the Cam734 F144A isoform
was intermediate to that of empty vector and wild-type PfCRT. This provides evidence that the
A144F mutation is critical for drug transport mediated by the Cam734 isoform and is consis-
tent with our drug assay data showing a CQR phenotype for parasites expressing Cam734 pfcrt
but not the F144A back-mutant (see Fig 1A). These PfCRT-specific phenotypes were not
attributable to differences in protein expression, as comparable protein expression of PfCRT
variants was observedupon galactose induction of yeast (S6B Fig).
Fig 5. Parasite growth and percentage of free heme as a function of CQ concentration for recombinant isogenic pfcrt-modified parasites.
Curves show parasite growth (black curve) and percentage of free heme species (gray curve), graphed as a function of the log10-transformed CQ
concentration (in nM). Plotted points and error bars correspond to mean ± SEM measurements made in parasite growth assays (n = 8–10) or heme
fractionation assays (n = 5–10), as detailed in Materials and Methods.
doi:10.1371/journal.ppat.1005976.g005
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Differential effects of PfCRT isoforms on parasite digestive vacuole pH
and volume
Investigations utilizing the entrapment of a dextran-conjugated NERF to probe the pH and
volume of the parasite DV have previously documented the ability of PfCRT mutations to alter
DV physiology [40,76,77]. Using similar methods (see SupplementaryMaterials andMeth-
ods), we determined the DV pH and volume in isogenic GC03 parasites encodingGC03, Dd2,
Cam734 or Cam734 F144A PfCRT, in the presence or absence of CQ concentrations corre-
sponding to twice the CQ 50% lethal dose (LD50; see SupplementaryMaterials andMethods).
From smallest to largest DV volume, as well as frommost alkaline to most acidic DV pH, we
observed the order of parasite lines to be: GC03GC03, GC03Cam734 F144A, GC03Cam734, and
GC03Dd2 (S7 Table). This order was preserved upon a brief (30 min) addition of CQ, which
consistently increasedDV volume (by 13% to 33%).
Discussion
To ensure successful progression through their life cycle, drug-resistant P. falciparum parasites
must balance the acquisition of resistance properties with the maintenance of required and
often interrelated physiological processes. Focusing on the pathogenic intraerythrocyticstages
of parasite growth, we explored herein how novel mutations comprising the unusually poly-
morphic Cam734 PfCRT variant contribute to this complex relationship. Our analysis of
isogenic, pfcrt-modified lines reveals that multiple PfCRT mutations possess dual roles, con-
tributing to both quinoline resistance and parasite proliferation. This was most notable for the
A144F mutation that is unique to Cam734 PfCRT, which in addition to affecting growth rates
proved to be indispensable for parasite resistance to multiple quinoline-type compounds,
including CQ, QN, and the first-line ACT partner drug AQ. While these drug IC50 shifts are
often relatively small, studies have shown that these translate into clear patterns of selection
in field parasite populations [7,12]. The pleotropic requirement for the A144F mutation in
Cam734 PfCRT-mediated drug resistance is reminiscent of earlier work, in which back-muta-
tion of K76T ablated CQR and nearly halved the degree of parasite resistance to QN [52].
GC03Cam734 F144A parasites appeared CQ-sensitive, but nonetheless showed a 3–fold higher
Fig 6. Effect ofΔψ on CQ-induced growth inhibition of yeast expressing PfCRT isoforms. Growth (measured as OD600) of yeast harboring no
(empty vector; solid black line), wild-type (GC03; gray line), Cam734 (blue line), Cam734 F144A (red line) or Dd2 (dashed black line). Growth was
assessed in the presence of 5 mM CQ in conditions of low Δψ (left panel; pHexternal 7.20) or high Δψ (right panel; pHexternal 7.45), as detailed in Materials
and Methods. Increased growth inhibition correlates with increased CQ accumulation in the yeast cytosol and reflects increased CQR [75]. Δψ
increases with increased pHexternal due to compensatory mechanisms that maintain the electrochemical gradient across the cell membrane. Growth of
yeast lines over the pHexternal range of 7.20–7.45 is surveyed in S6A Fig.
doi:10.1371/journal.ppat.1005976.g006
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IC90 value for md-CQ, believed to be the major driver of selection for mutant pfcrt [16], relative
to the fully sensitive GC03GC03 line (S2 Table). By comparison, GC03Cam734 parasites showed a
27–fold md-CQ IC90 increase. Similar findings were earlier observedwith a PfCRT variant of
7G8 that carries the C350Rmutation (the H209 isolate found in French Guiana) [50,60]. This
variant was shown to mediate a phenotype of CQ tolerance, which manifested as low CQ IC50
values but elevated md-CQ IC90 values as well as parasite recrudescenceafter exposure to CQ
concentrations lethal to CQ-sensitive parasites expressing wild-type pfcrt [50,60]. We note that
parasites encodingCam734 F144A PfCRT retained K76T as well as 7 other mutations [7]. The
clear importance of mutations other than K76T in contributing to CQR can help explain, in
areas where novel PfCRT variants have arisen, why the K76T mutation predicts clinical CQR
with good sensitivity but only moderate specificity [17,62]. Another important factor driving
the reduced specificity of the K76T marker is patient immunity, which in higher-transmission
settings of Africa is known to help resolve CQ-resistant infections in CQ-treated patients [78].
Prior studies with asexual blood stage parasites have shown that CQ affects heme disposi-
tion (increasing free heme and reducing Hz) and that CQ access to its heme target in the DV
is significantly reduced by CQ-resistant mutant forms of PfCRT, which are thought to efflux
CQ away from the DV [32,38,52]. We built on these observations by comparing wild-type
and variant PfCRT isoforms expressed on the same genetic background. Our results, shown
in Figs 4 and 5, provide compelling evidence that the degree of CQ-mediated inhibition of
parasite growth is closely correlated with the level of inhibition of Hz formation. ReducedHz
formation was accompanied by the accumulation of reactive free heme, which at high con-
centrations is presumably the major trigger of parasite death, either alone or conjugated to
CQ [7]. Recombinant GC03 parasites expressing the mutant PfCRT Dd2 and Cam734 iso-
forms (i.e. GC03Cam734 and GC03Dd2) differed notably from the isogenic clone expressing the
wild-typeGC03 isoform (GC03GC03) in that accumulation of free heme occurred at higher
CQ concentrations in the former. Increased free heme was accompanied by lower levels of
Hz, consistent with mutant PfCRT being able to efflux drug away from its heme target. Both
mutant pfcrt-expressing lines also showed reduced levels of heme at low concentrations of
CQ or at baseline (no CQ), suggesting a more efficient process of Hz formation under those
conditions. The reason for this difference in baseline free heme is not yet known. Evidence
suggests that free heme in untreated parasites is sequestered, possibly through association
with neutral lipids in the DV [79]. The baseline difference betweenwild-type and mutant
pfcrt-expressing parasites may thus be attributed to the larger DV of GC03Dd2 and
GC03Cam734 lines, as compared to GC03GC03 parasites (see below and S7 Table), resulting in
a lower lipid to aqueous volume ratio. Indeed, a fixed lipid-aqueous portioning coefficient
and fixed ratio of lipid to aqueous heme concentration would yield an increased quantity of
aqueous free heme (volume × concentration), which in turn would be mostly incorporated
into Hz.
With all three lines, levels of undegradedHb also rose at relatively high CQ fold IC50 con-
centrations, with the highest levels recorded in the GC03Cam734 and GC03Dd2 lines (see Fig
4C), potentially reflecting increased CQ amounts in the cytosol of these parasites because of
higher rates of CQ efflux from the DV. These results expand on the previous observation,
in CQ-treated drug-sensitive parasites, that increases in undigestedHb follow significant
increases in free heme [32]. This suggests a secondarymode of CQ action, whereby Hb proteol-
ysis is inhibited at higher CQ concentrations, possibly through a physiologic effect of elevated
CQ concentrations on Hb endocytosis or the activity of DV-resident hemoglobinases [80,81].
Alternatively, elevated concentrations of free heme in aqueous environments have been shown
to form heme aggregates capable of disrupting lipid bilayers and triggeringmembrane disorder,
which in turn could disrupt Hb import and catabolism [82].
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Ourmetabolomics analysis (see Fig 3) and total Hb quantification (see Fig 4C and S5C Fig)
reveal major changes in the Hb digestion pathway in the GC03Cam734 line when compared with
the isogenic lines GC03Dd2 and GC03Dd2 lines. Given that these changes have been associated
with impaired fitness in mutant PfCRT parasites expressing the CQ resistance-conferringDd2
or 7G8 haplotypes [41], our results raise an obvious question: does Cam734 PfCRT impart a
metabolic compensatory mechanism that allows these parasites to circumvent the normally
deleterious effects of altered Hb digestion? Previous heterologous expression studies using
Xenopus laevis oocytes have suggested that mutant PfCRT isoforms might selectively confer
transport of the tripeptide glutathione [57], which was earlier proposed to facilitate the degra-
dation of reactive heme and reduce heme-mediated toxicity [36,83]. However, we saw no sig-
nificant differences in glutathione or any other redox-associatedmetabolites (see S4 Fig and S6
Table) between isogenic lines encodingCam734 or Dd2 PfCRT, suggesting that major redox-
related metabolic changes are unlikely to account for the improved fitness associated with the
Cam734 pfcrt allele. In contrast, we observed significant differences in ATP/AMP ratios and
central carbonmetabolism between lines encoding Cam734 and Dd2 PfCRT (see Fig 3 and S6
Table), implicating changes in energymetabolism as a potential physiologically compensatory
mechanism.
Our heterologous yeast expression studies also found that Cam734 is significantly affected
by Δψ, resembling a CQ-sensitive PfCRT isoform at low Δψ and a mutant, CQ-resistant PfCRT
isoform at high Δψ. This unique plasticity in mediating drug transport may underlie the
improved asexual blood-stage fitness associated with the Cam734 PfCRT isoform, as compared
with Dd2 (see Fig 2), whereby Cam734-definingmutations confer drug transport only in cer-
tain Δψ DV conditions.We also note that CQ transport, as assessed in heterologous expression
systems, may only partially account for in vitro parasite CQR. This is highlighted by the earlier
observation that the CQ-resistant Ecu1110 PfCRT variant (K76T/A220S/N326D/I356L) con-
fers lower parasite CQR, but higher CQ transport, than the related 7G8 PfCRT variant (that in
addition carries the C72S mutation) [16,23,77]. The Cam734 isoformmight therefore facilitate
CQR in part by alleviating CQ-mediated inhibition of an endogenous PfCRT function. Contin-
ued elucidation of the elusive function of PfCRT will assist in clarifying these distinctions.
Our physiological studies of isogenic pfcrt-modified lines revealed that the DV pH and vol-
ume parameters in GC03Cam734 parasites were intermediate to GC03GC03 and GC03Dd2 para-
sites, consistent with the Cam734 allele producing CQ IC50 values between the sensitive wild-
type and highly-resistant Dd2 isoforms. In all three isogenic lines, brief exposure to CQ caused
DV swelling, with the more CQ-resistant parasites showing the greatest increase in DV volume
(S7 Table). As the composition of the DV environment governs the degree of heme-to-Hz con-
version [38], we propose that, compared to Dd2 PfCRT, the reducedDV size and more wild-
type (GC03) PfCRT-like DV pH associated with the Cam734 isoformmight play a role in neu-
tralizing the fitness costs typically associated with mutant PfCRT variants.
Recent evolutionary genetic studies of the adaptive landscapes (i.e. mutational paths and
their accompanying fitness costs) associated with drug resistance-conferringmutations in pfcrt
and P. falciparum dihydrofolate reductase (dhfr) highlight key considerations when hypothe-
sizing how Cam734 pfcrtmight have evolved: (1) forward pfcrt evolution is a physiologically
constrained process that is consistent with the rarity of pfcrt alleles bearing three or fewer poly-
morphisms; (2) forward and reverse processes of gene evolution are associated with distinct
adaptive landscapes; and (3) adaptive landscapes can be substantially modified by their drug
environment [16,84–86]. The spread of CQR in Asia and Africa has long been attributed to a
single (Dd2 or Dd2-like) pfcrt allele [4]. Of note, Cam734 shares four of the eight mutations
comprising both the eight-amino acid Dd2 variant (see Table 1) and the related 6-amino acid
variant GB4 (equivalent to Dd2 S326N T356I) found in Africa and also seen in Southeast Asia.
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Our recent analysis of close to 900 Asian P. falciparum genomes recently sequenced by the
Pf3K consortium [87] estimates the prevalence of Cam734, GB4 and Dd2 pfcrt alleles at 15%,
13% and 58% respectively, with the remainder comprising the wild-type allele (3%) and several
minor variants. For Cam734, the highest abundance was observed in Cambodia (105 of 570
genomes), Laos (29 of 85) and Vietnam (32 of 97), with a far lower prevalence in Thailand (1
of 148). We posit that, faced with high CQ pressure, parasites underwentmutational bursts (as
previously suggested [16]) that led to the evolution of Dd2 pfcrt. With reduced CQ pressure, a
“reverse” evolutionary process might have led to the loss of some mutations and eventual
acquisition of novel ones, as in the case of Cam734 pfcrt.
In their report documentingCam734 pfcrt in Cambodia,Durrand et al. also reported the
related allele Cam738 (akin to Cam734 without the A144F mutation) [47]. We posit that
Cam738 served as a mutational precursor of the more evolutionarily successful Cam734 allele.
This is supported by the inferior growth of isogenic parasites expressing Cam738 pfcrt as com-
pared with Cam734 pfcrt, in the absence or presence of CQ or other quinoline drugs (see Figs
1B and 2). Our evidence of reduced growth rates of parasites harboring the Cam738 allele com-
pared with Cam734 is consistent with the absence of Cam738 haplotypes in the recent Pf3K
genome data set (https://www.malariagen.net/projects/pf3k).We also note that selective
forces favoring mutation of PfCRT residue 144, found herein to be a key mediator of CQR, are
apparent in Asia, in some cases requiring two nucleotide substitutions. For example, in the
Philippines or in China, PfCRT haplotypes have been detected that, respectively, harbor the
mutations A144T or A144Y [88,89]. Interestingly, addition of A144Y to the CQ-resistant Dd2
PfCRT isoform was previously found to abrogate CQ transport in S. cerevisiae [22].
With sustained exposure to drug selective forces, parasites may evolve intragenic and/or
intergenic compensatory changes that allow them to persist even in the absence of drug pres-
sure [90]. The Cam734-defining compensatory mutations identified in our analysis reveal an
intragenic basis for the enhanced fitness of this CQ-resistant allele, which could explain its
continued presence in Southeast Asia as a minor allele despite the lack of CQ use for several
decades to treat P. falciparummalaria.We note that CQ resistance-conferringmutant pfcrt
alleles (including Cam734 and Dd2) might also persist in Southeast Asia because of local con-
ditions of decreased genetic diversity and complexity of infections, resulting in less competition
among parasite lines, as compared with high-endemicity settings in sub-Saharan Africa, where
mutant pfcrt alleles are known to rapidly decrease in prevalence in areas without CQ pressure
[7].
The degree to which secondary genetic factors also play a role in maintaining mutant pfcrt
in Southeast Asia is presently unclear. We note that our pfcrt-modified lines were generated in
GC03 parasites, a clone of the HB3 (Central America) × Dd2 (Asia) genetic cross [91]. These
parasites encode the HB3 PfMDR1 haplotype, which differs from Dd2 PfMDR1 at three dis-
tinct residues (86, 184, 1042) [92]. A recent study has shown that the PfMDR1 N86Ymutation
present in Dd2 augments the degree of CQR imparted by the mutant Dd2 PfCRT isoform [15].
We have observed in prior transfection-based studies that the parasite genetic background dic-
tates the level to which mutant pfcrt alleles can mediate CQR [50]. Of note, results obtained
herein in GC03 parasites might potentially differ from ones that would be produced with cul-
ture-adapted field isolates that naturally harbor the pfcrt Cam734 allele. However, to the best of
our knowledge, no such isolate has been culture-adapted and reported in the literature. Fur-
thermore, GC03 has been the primary strain used in multiple prior pfcrt transfection studies,
using either the ZFNmethod or the earlier approach that used single-site crossovers, thus pro-
viding a benchmark against which to assess the current data set [11,16,42,48,50].
The notion that additional genetic changes are required to produce high-level CQR in para-
sites encodingCam734 PfCRT evokes a previous finding that mutant PfCRT-encoding parasites
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can exhibit increased expression of proteins involved in pH regulation, including a V-type H+
pyrophosphatase [93]. Our observation that, compared with Dd2, Cam734 PfCRT required a
higher Δψ to manifest increased growth in the presence of CQ (consistent with elevated drug
transport; see Fig 6) suggests that high-level Cam734 PfCRT-mediated drug resistance may be
potentiated by parasite proteins that govern the Δψ across the DV membrane. We speculate that
this plasticity in drug transport might be a reflection of the balance that Cam734 PfCRT has
achieved in mediating resistance while also avoiding fitness costs. Future genetic dissections of
pfcrt alleles, as well as candidate secondary geneticmodulators (e.g. pfmdr1), are possible with
the recent advent of efficient parasite ZFN or CRISPR/Cas9–basedgenome-editing tools
[15,94]. Leveraging these approaches with analysis of parasite whole-genome sequences will aid
in deciphering the genetic complexities that underlie new and emergingmultidrug resistance
phenotypes.
Materials and Methods
Parasite cultivation and genetic modification
P. falciparum asexual blood-stage parasites were cultured in human RBCs (Interstate Blood
Bank) at 2–4% hematocrit in RPMI-1640-basedmalaria cell culture medium supplemented
with 0.5% Albumax II (Invitrogen) [95]. Cultures were incubated at 37°C in 5% O2 / 5% CO2 /
90% N2. Geneticmodification of the parasite pfcrt locus is detailed in SupplementaryMateri-
als andMethods and S1 Fig.
Drug susceptibility assays
Drug inhibitory concentrations that result in 50% (IC50) or 90% (IC90) growth inhibition were
determined for a panel of drugs (CQ ± 0.8 μM VP, md-CQ, md-AQ, QN, PPQ, LUM, AS, and
PND), as described [50]. After 72 h exposure to drug, parasite growth was quantified by stain-
ing with SYBR Green I and MitoTracker Deep Red and measuring parasitemia on an Accuri
C6 flow cytometer. Reversibility of CQR by 0.8 μM VP was expressed as the CQ RMI, equiva-
lent to the quotient of the CQ+VP IC50 divided by the CQ IC50 [63]. Statistical significancewas
determined via non-parametricMann-Whitney U tests using GraphPad Prism 6 software.
In vitro growth assays
As a proxy for in vitro fitness, growth of parasite lines was assessed in 1:1 co-culture assays
with the fluorescent reporter line NF54eGFP, using previously describedmethods [16]. Briefly,
1:1 co-cultures consisting of the reporter line (GFP+) and individual pfcrt-modified test lines
(GFP−) were propagated for 10 generations, and parasitemias were maintained between 0.3%
and 8%. The proportion of GFP− parasites was regularly determined by flow cytometric detec-
tion of the far-red fluorescent dye SYTO61, which labels the nuclei of infected RBCs (iRBCs),
and GFP. Derivation of per-generation selection coefficients (s) of test strains is detailed in
SupplementaryMaterials andMethods. Statistical significancewas assessed via two-way anal-
ysis of variance (ANOVA) with Sidak’s post-hoc test using GraphPad Prism 6 software.
Metabolite extraction and mass spectrometric analysis
All parasite culturing,metabolite extraction,mass spectrometrydata acquisition, and data
analyses were conducted using previously established methods [41]. Briefly, after double syn-
chronization with 5% sorbitol, late-stage (~36–42 h) P. falciparum trophozoites were magneti-
cally purified using a SuperMACS magnetic separator (Miltneyi Biotec) and CS columns.
Eluted iRBCswere resuspended at 0.4% hematocrit and allowed to recover for 2 h at 37°C in a
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tissue culture incubator. Cells were then rapidly cooled to 4°C and pelleted by centrifugation at
2,000×g for 5 min. Media was then aspirated away from the iRBC pellets and metabolites were
extracted by resuspending cells in cold (4°C) 90%methanol. Samples were homogenized by
vortexing and centrifuged at 10,000×g for 5 min at 4°C. The supernatant metabolite extracts
were harvested and stored at -80°C until mass spectrometryanalysis. Just prior to mass spec-
trometry, samples were dried under a stream of N2 and were resuspended in HPLC-grade
water at a 4:1 dilution (relative to the original iRBC pellet volume). High-resolutionmass spec-
trometry data were acquired on a Thermo Fisher ExactiveMass spectrometer in negative mode
using 25 min reverse phase gradients and ion-pairing chromatography [41]. Metabolites were
identified using the known chromatographic retention times of standards, and metabolite sig-
nals were quantified using MAVEN [41]. To allow for more direct metabolite-to-metabolite
comparison of phenotypes, raw mass spectrometry signals were expressed as z-scores. Briefly,
for each metabolite, the mean expected signal (x) was defined as the mean intensity observed
in the control line (GC03Dd2). Likewise, the standard deviation (s) for each metabolite signal
was calculated from signals observed in the GC03Dd2 line (deduced from 3 independent har-
vests with 4 replicates). The z-score (zi) for each observed signal (xi) in test lines was then com-
puted as per the relationship zi ¼ ½xi   x=s and plotted according to metabolite class. For
summary statistics (Fig 3), z-scores were calculated from the signals observed for each class.
These classes were comprised of metabolites that are directly associated with a metabolic path-
way (e.g. TCAmetabolism included TCA intermediates as well as the TCA-associated amino
acid glutamate). P values were computed by one-way ANOVA. All data analyses and statistical
tests were conducted using custom in-house software written in R. Metabolite signal intensities
are summarized in S5 Table. Metabolite z-scores and associated P values are found in S6 Table.
Heme fractionation experiments
The heme fraction profiles of pfcrt-modifiedGC03GC03, GC03Dd2, and GC03Cam734 parasites
were determined following recently published and validated protocols [73]. First, parasite
growth in response to CQwas determined using the lactate dehydrogenase assay [96]. Heme
fractionation assays were then initiated by incubating sorbitol-synchronized, early ring-stage
parasites in the absence or presence of CQ in multiples (0.5×, 1×, 2×, 2.5×, and 3×) of the bio-
logical CQ IC50. After 32 h, iRBCswere treated with 1% saponin to release mature trophozo-
ites, followed by hypotonic lysis and centrifugation. Supernatants were treated with 2% SDS
and 2.5% pyridine, yielding the Hb fraction. Pyridine was used as it coordinates to heme form-
ing a monomeric low-spin complex with a distinctive spectrumand is easily detectable by UV-
visible spectroscopy, thereby allowing heme species to be quantified. Pellets were treated with
2% SDS and 2.5% pyridine, sonicated, and centrifuged, and supernatants were removed to
isolate the free heme fraction. The remaining pellets were solubilized in 2% SDS and 0.1 M
NaOH, sonicated, neutralizedwith HCl, and treated with 2% SDS and 2.5% pyridine to gener-
ate the Hz fraction. For each fraction, the UV-visible spectrumof heme present as a heme-pyri-
dine complex was measured with a multi-well plate reader (Spectramax 340 PC, Molecular
Devices). The abundance of Hb, free heme, and Hz species was reported as a percent and as an
absolute amount of heme Fe per cell. Parasites were quantified using flow cytometry, as previ-
ously described [73]. Statistical significancewas assessed via unpaired t tests withWelch’s cor-
rection using GraphPad Prism 6 software.
Yeast drug transport assays
Cultivation, transfection, and quantitative growth rate analysis of S. cerevisiae yeast strains
employed previously detailed protocols [22,75]. Briefly, CH1305 yeast strains were transfected
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with either pYES2 (blank vector) or pYES2-derived plasmids encoding the galactose/raffinose-
inducible, codon-optimizedPfCRT isoforms GC03 (HB3; wild-type), Cam734, Cam734 F144A
(also known as Cam738), or Dd2. Quantitative assessment of yeast growth, a validated proxy
for CQ transport [74], was performed in PfCRT-inducing (galactose/raffinose)or PfCRT-non-
inducing (glucose) conditions, with a starting cell density (OD600) of 0.1. Yeast growth ± 5 mM
CQwas measured in triplicate with a Tecan GENios microplate reader following established
parameters [22]. PfCRT protein expression of yeast lines was evaluated usingWestern blot
analysis, demonstrating comparable protein levels across all lines (see SupplementaryMateri-
als andMethods and S6B Fig).
Supporting Information
S1 Text. SupplementaryMaterials andMethods.
(DOCX)
S1 Fig. Geneticmodificationof the pfcrt locus via zinc-finger nucleases (ZFNs). (A)Genetic
engineering strategy. Briefly, parasites were transfected with a donor template plasmid (pcrt-
hdhfr) with the coding region corresponding to exons 2 to 13 (e2-13) of a pfcrt allele of interest
(indicated in purple; see Table 1 for full list of pfcrt alleles). Donor plasmids also include the
following: a P. berghei crt (pbcrt) 30 untranslated region (UTR) sequence, a human dhfr (hdhfr)
selection cassette, and flanking left (~0.4 kb upstream of the intron 1-exon 2 boundary) and
right (~1 kb native 30 UTR) homology regions [48]. Donor plasmid-enriched parasites were
transfected with pZFNcrt-bsd, which encodes a pair of pfcrt-specificZFNs (ZFNL and ZFNR)
via the calmodulin (cam) promoter and includes the blasticidin S deaminase (bsd) selection cas-
sette. Operating as an obligate heterodimer, ZFNL and ZFNR catalyze a double-strandedDNA
break in the pfcrt intron 1-exon 2 region (indicated with a red bolt). Recombinant parasites
that were successfully generated via DNA repair mechanisms encode pfcrt exon 1 as well as the
e2-13 sequence bearingmutations of interest. Recombinant parasites were cloned by limiting
dilution, their genetic editing verified by diagnostic PCR (see S1B Fig), and sequence integrity
verified at the DNA and RNA levels. (B)Diagnostic PCRs of representative recombinant para-
sites encoding full-length (GC03Cam734) and back-mutated (GC03Cam734 F144A) pfcrt alleles.
Controls include genetically unedited parental parasites (GC03), unedited donor plasmid-
enriched parasites (GC03 + either pcrtCam734-hdhfr or pcrtCam734 F144A-hdhfr) and donor plas-
mids alone (pcrtCam734-hdhfr or pcrtCam734 F144A-hdhfr). Primer (p) locations are illustrated in
S1A Fig. PCR amplicons for ZFN-edited lines demonstrated the expected sizes of 0.4 kb (p5
+p6), 1.2 kb (p7+p6), 2.5 kb (p8+p9), and 2.7 kb (p7+p10). (C)Western blot analysis of iso-
genic pfcrt-modifiedparasite lines showing equivalent PfCRT protein expression levels, as
detected using anti-PfCRT primary antibodies that identify the ~42 kDa protein as expected
[10]. Antibodies to the ~25 kDa PfERD2 protein were used as a reference. We note that our
recent study by Gabryszewski et al. [16], which employed the identical ZFN approach used
herein, examined PfCRT protein expression levels in seven pfcrt-modified lines. Results
showed no more than a 10% difference on average between any two given lines, with none of
these differences being statistically significant. There was also no correlation between PfCRT
protein levels and either the degree of CQ resistance or the rates of in vitro parasite growth. In
earlier studies with the former single-site crossover method, we compared protein expression
levels in a panel of pfcrt-modified lines, which also showed no significant difference between
lines and no correlation with CQ IC50 values [11,42,50,52]. Of note, the new ZFNmethod has
the major benefit that it does not result in an appreciable reduction in protein expression levels,
unlike the earlier single-site crossover method that retained downstream partial gene fragments
and showed lower levels of expression of the full-length recombinant protein compared to
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non-modified lines.
(EPS)
S2 Fig. Parasite responses to lumefantrine, artesunate, and pyronaridine. Following 72 h
exposure of parasites to the indicated antimalarial drugs, parasite growth was assessed using
flow cytometry, as detailed inMaterials andMethods. Bar graphs correspond to mean ± SEM
IC50 values. Results encompass 2 to 12 independent assays conducted in duplicate. Statistical
differences were determined via non-parametricMann-Whitney U tests, using the mean IC50
value of Cam734 pfcrt-expressing GC03Cam734 parasites as the comparator. IC50 and IC90 val-
ues and Hill slopes are summarized along with corresponding statistical tests in S2 Table.
P<0.05; P<0.01; P<0.001. P<0.0001.
(EPS)
S3 Fig. In vitro growth plots of pfcrt-modifiedand reference parasites.Co-cultures consist-
ing of 1:1 proportions of individual GFP-negative (GFP−) test lines and a GFP-positive (GFP+)
reporter line were seeded at day 0 and regularly monitored by flow cytometry for 10 parasite
generations (seeMaterials and Methods). Three independent assays were conducted in dupli-
cate in the absence or presence of a sub-lethal dose of CQ (7.5 nM, equivalent to ~0.5× CQ
IC50 of the CQ-sensitive line GC03GC03). (A) Plots of the mean ± SEM proportion of GFP− test
lines (p) as a function of number of parasite generations (t). GFP+ (reporter line only) and
GFP− (GC03GC03 only) control (ctrl) lines exhibited steady fluorescence levels over the dura-
tion of the experiment. (B) Plots of mean ± SEM natural log (ln)-transformed ratios of the pro-
portion of a GFP− test line to the GFP+ reporter line at time t (pt/qt). This parameter was used
to derive in vitro growth selection coefficients (s), as detailed in SupplementaryMaterials and
Methods.
(EPS)
S4 Fig. Individualmetabolite profiles of isogenic,mutant pfcrt-expressingparasites.Metab-
olite extracts were derived from tightly synchronized trophozoite-stage isogenic (GC03) para-
sites encoding either Dd2 or Cam734 pfcrt and analyzed by mass spectrometry. Metabolite
signals were converted to z-scores (seeMaterials and Methods). Each bar shows the z-score for
an experimental replicate obtained for GC03Dd2 (black) or GC03Cam734 (red) parasites. Dashed
lines represent lower (5%) and upper (95%) boundaries for the normal distribution, as defined
for GC03Dd2 parasites. Metabolites were harvested on three independent occasions (n = 4 to 6
total replicates per parasite strain). Metabolite z-scores, P values, and full names of individual
metabolites are detailed in S6 Table. TCA, tricarboxylic acid; PPP, pentose phosphate pathway;
Nt, nucleotide; AA, amino acid; NAc, N-Acetylated.
(EPS)
S5 Fig. Absolute concentrations of heme species in control and chloroquine (CQ)-treated
pfcrt-modifiedparasite lines.The amount in femtograms (fg) of heme Fe per cell present as
(A) free heme, (B) hemozoin (Hz), or (C) hemoglobin (Hb) was measured spectrophotometri-
cally in isogenic parasites expressing the wild-type (CQ-sensitive) GC03 pfcrt allele or mutant
(CQ-resistant) Dd2 and Cam734 pfcrt alleles. Prior to heme fractionation, synchronous para-
sites were exposed for 32 h to CQ concentrations corresponding to line-specificCQ IC50
folds (1× CQ IC50 values of 19.5 nM, 187 nM, and 90.9 nM for GC03GC03, GC03Dd2, and
GC03Cam734, respectively. In absolute values, 0.5× CQ IC50 for GC03Cam734 is equivalent to
2.3× the CQ IC50 for GC03GC03 and 0.25× the CQ IC50 for GC03Dd2). Bar graphs indicate
mean ± SEM percentage values for 5 to 8 technically independent replicates. For each parasite
line, values obtained for CQ-treated samples (gray bars) were compared against the untreated
control (black bars), and statistical significancewas determined via unpaired t tests with
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Welch’s correction. P<0.05; P<0.01; P<0.001. P<0.0001.
(EPS)
S6 Fig. Membrane potential (Δψ) dependenceof PfCRT-mediated yeast growth delay and
PfCRT isoform expression. (A)Growth delay of yeast lines encodingwild-type (gray dia-
monds), Dd2 (black squares), Cam734 (blue triangles), or Cam734 F144A (red triangles, also
known as Cam738) PfCRT was measured in the presence of 5 mMCQ and normalized to
growth of yeast harboring empty vector (seeMaterials and Methods). These PfCRT isoforms
were tagged to a V5 epitope at their C terminus [75]) Growth was examined for a range (7.20
to 7.45) of pHexternal values. Through compensatory mechanisms, the yeast Δψ increases with
increased pHexternal. CQ transport rates were calculated as previously described [75]. Error bars
indicate the SEM for at least three independent yeast clones analyzed in triplicate. (B) Yeast
protein extracts were subjected to Western blot analysis with anti-V5 antibodies, as described
in SupplementaryMaterials andMethods. Briefly, total protein concentrations in the yeast
crudemembrane fractions were quantified using an amido black assay and 7.0 μg of protein
per sample was electrophoretically separated and transferred onto a PVDFmembrane. Levels
of the 51.8-kDa PfCRT-V5 protein were comparable for all PfCRT isoforms (GC03, Dd2,
Cam734, and Cam734 F144A). A yeast strain harboring an empty vector was included in the
analysis as a negative control.
(EPS)
S1 Table. Primers used in this study. Nucleotides corresponding to restriction sites are under-
lined. F, forward; R, reverse; gDNA, genomic DNA; pbcrt, P. berghei chloroquine resistance
transporter;UTR, untranslated region.
(PDF)
S2 Table. Antimalarial IC50 and IC90 values of pfcrt-modifiedand reference parasite lines.
IC50 and IC90 values (nM) indicate the mean ± SEM, as determined in 2 to 12 independent
assays performed in duplicate. CQ + VP assays were performedwith 0.8 μM VP. CQ,
chloroquine; VP, verapamil; md-CQ, monodesethyl-chloroquine;md-AQ, monodesethyl-
amodiaquine; QN, quinine; PPQ, piperaquine; LUM, lumefantrine; AS, artesunate; PND, pyro-
naridine; n, number of assays. P values were determined in a non-parametricMann-Whitney
U test versus the parasite line GC03Cam734. P values<0.05 are indicated in bold and shaded in
gray. Hill slopes were calculated from the dose-response data using GraphPad Prism 6 soft-
ware.
(PDF)
S3 Table. Verapamil-mediated CQ resistance reversibility of pfcrt-modifiedand reference
parasite lines.Reversibility of chloroquine (CQ) resistance by 0.8 μM verapamil (VP) is indi-
cated as the CQ response modification index (RMI), equivalent to (IC50 for CQ+VP) (IC50
for CQ only). Shown are mean RMI ± SEM values, as determined in 5 to 12 independent
assays. n, number of assays. P values were determined in a non-parametricMann-Whitney U
test versus the parasite line GC03Cam734. P values<0.05 are indicated in bold and shaded in
gray.
(PDF)
S4 Table. In vitro growth selection coefficientsof pfcrt-modifiedand reference parasite
lines. Parasite in vitro growth was evaluated in the absence or presence of a sub-lethal dose of
CQ (7.5 nM; ~0.5× CQ IC50 of the CQ-sensitive reference line GC03GC03) and normalized
against GC03Cam734 in the absence of drug pressure (6 total replicates per condition). As
detailed inMaterials andMethods, the per-generation selection coefficient (indicated above as
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s ± SEM) was derived from the relative fitness index (ω') as per the relationship s = ω'– 1, such
that s<0 and s>0 respectively indicate growth inferior or superior to the GC03Cam734 parasite
line, which encodes the full-lengthCam734 pfcrt allele. CQ, chloroquine; P1, P value for inter-
strain comparisons, determined versus the parasite line GC03Cam734 using two-way ANOVA
with Sidak’s post-hoc test; P2, P value for intra-strain comparisons, determined for a given par-
asite strain in the absence versus presence of 7.5 nM CQ using two-way ANOVA with Sidak’s
post-hoc test. P values<0.05 are indicated in bold and shaded in gray.
(PDF)
S5 Table. Metabolite mass spectroscopy signal intensities.Mass spectrometric signal intensi-
ties for metabolites derived from trophozoite-stage isogenic (GC03) parasites encoding either
Dd2 or Cam734 pfcrt, as detailed inMaterials andMethods. Metabolites were harvested on
three independent occasions, yielding 4 and 6 individual replicates (r) for the GC03Dd2 and
GC03Cam734 strains, respectively.
(PDF)
S6 Table. Metabolite z-scores and P values.Metabolite classes and individual metabolite z-
scores (seeMaterials and Methods for z-score derivation). P values were determined using
one-way ANOVA. Correspondingmetabolite signal intensities are reported in S5 Table.
Metabolites were harvested on three independent occasions, yielding 4 and 6 individual repli-
cates (r) for the GC03Dd2 and GC03Cam734 strains, respectively. P values<0.05 are shaded in
gray.
(PDF)
S7 Table. Digestive vacuole volume size and pH of pfcrt-modifiedlines. For the indicated
isogenic, pfcrt-modified lines, digestive vacuole (DV) volume size and pH were determined
using spinning disk confocal microscopy and single-cell photometry, respectively, as detailed
in SupplementaryMaterials andMethods. Measurements were made following 30 min expo-
sure to no drug or 2× CQ LD50. Results are reported as mean ± SEM DV volume size (μm3) or
pH, as determined for20 parasites, beginning in each case with tightly synchronized young
trophozoites. DV volume values for CQ-treated parasites were compared against those of
untreated controls to determine the percent increase in size.
(PDF)
Author Contributions
Conceptualization: SJG SKD JMC IAL PPH AHL TJE PDR DAF.
Formal analysis: SJG SKD JMC IAL PSCMRHASML TJE PDR DAF.
Funding acquisition: IAL ML TJE PDR DAF.
Investigation: SJG SKD JMC IAL PSCMRHAS PPH AHLNFG LM.
Project administration:DAF.
Supervision:ML TJE PDR DAF.
Validation: SJG SKD JMC IAL PSCMRHASML TJE PDR DAF.
Writing – original draft: SJG DAF.
Writing – review& editing: SJG IAL TJE PDR DAF.
Molecular Analysis of the Evolution of Fitness Cost-Neutral Mutant PfCRT
PLOS Pathogens | DOI:10.1371/journal.ppat.1005976 November 10, 2016 24 / 29
References
1. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, et al. Malaria. Lancet. 2014; 383
(9918):723–35. doi: 10.1016/S0140-6736(13)60024-0 PMID: 23953767.
2. Roper C, Pearce R, Nair S, Sharp B, Nosten F, et al. Intercontinental spread of pyrimethamine-resis-
tant malaria. Science. 2004; 305(5687):1124. doi: 10.1126/science.1098876 PMID: 15326348.
3. Fairhurst RM. Understanding artemisinin-resistant malaria: what a difference a year makes. Curr Opin
Infect Dis. 2015; 28(5):417–25. doi: 10.1097/QCO.0000000000000199 PMID: 26237549.
4. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, et al. Genetic diversity and chloroquine selective
sweeps in Plasmodium falciparum. Nature. 2002; 418(6895):320–3. doi: 10.1038/nature00813 PMID:
12124623.
5. Carter R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev.
2002; 15(4):564–94. PMID: 12364370. doi: 10.1128/CMR.15.4.564-594.2002
6. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001; 64
(1–2 Suppl):12–7. PMID: 11425173.
7. Ecker A, Lehane AM, Clain J, Fidock DA. PfCRT and its role in antimalarial drug resistance. Trends
Parasitol. 2012; 28(11):504–14. doi: 10.1016/j.pt.2012.08.002 PMID: 23020971.
8. Ursing J, Rombo L, Bergqvist Y, Rodrigues A, Kofoed PE. High-dose chloroquine for treatment of chlo-
roquine-resistant Plasmodium falciparum malaria. J Infect Dis. 2016; 213(8):1315–21. doi: 10.1093/
infdis/jiv590 PMID: 26656124.
9. Jones RA, Panda SS, Hall CD. Quinine conjugates and quinine analogues as potential antimalarial
agents. Eur J Med Chem. 2015; 97:335–55. doi: 10.1016/j.ejmech.2015.02.002 PMID: 25683799.
10. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, et al. Mutations in the P. falciparum
digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance.
Mol Cell. 2000; 6(4):861–71. PMID: 11090624.
11. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria
parasites conferred by pfcrt mutations. Science. 2002; 298(5591):210–3. doi: 10.1126/science.
1074045 PMID: 12364805.
12. Volkman SK, Neafsey DE, Schaffner SF, Park DJ, Wirth DF. Harnessing genomics and genome biol-
ogy to understand malaria biology. Nat Rev Genet. 2012; 13(5):315–28. doi: 10.1038/nrg3187 PMID:
22495435.
13. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to
multiple antimalarials in Plasmodium falciparum. Nature. 2000; 403(6772):906–9. doi: 10.1038/
35002615 PMID: 10706290.
14. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and
enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol. 2005; 57
(4):913–26. doi: 10.1111/j.1365-2958.2005.04729.x PMID: 16091034.
15. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnadig N, et al. Globally prevalent PfMDR1 mutations
modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Com-
mun. 2016; 7:11553. doi: 10.1038/ncomms11553 PMID: 27189525.
16. Gabryszewski SJ, Modchang C, Musset L, Chookajorn T, Fidock DA. Combinatorial genetic modeling
of pfcrt-mediated drug resistance evolution in Plasmodium falciparum. Mol Biol Evol. 2016; 33
(6):1554–70. doi: 10.1093/molbev/msw037 PMID: 26908582.
17. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, et al. A molecular marker for chloroquine-
resistant falciparum malaria. N Engl J Med. 2001; 344(4):257–63. doi: 10.1056/
NEJM200101253440403 PMID: 11172152.
18. Juge N, Moriyama S, Miyaji T, Kawakami M, Iwai H, et al. Plasmodium falciparum chloroquine resis-
tance transporter is a H+-coupled polyspecific nutrient and drug exporter. Proc Natl Acad Sci U S A.
2015; 112(11):3356–61. doi: 10.1073/pnas.1417102112 PMID: 25733858.
19. Maughan SC, Pasternak M, Cairns N, Kiddle G, Brach T, et al. Plant homologs of the Plasmodium fal-
ciparum chloroquine-resistance transporter, PfCRT, are required for glutathione homeostasis and
stress responses. Proc Natl Acad Sci U S A. 2010; 107(5):2331–6. doi: 10.1073/pnas.0913689107
PMID: 20080670.
20. Reeves DC, Liebelt DA, Lakshmanan V, Roepe PD, Fidock DA, et al. Chloroquine-resistant isoforms
of the Plasmodium falciparum chloroquine resistance transporter acidify lysosomal pH in HEK293 cells
more than chloroquine-sensitive isoforms. Mol Biochem Parasitol. 2006; 150(2):288–99. doi: 10.1016/
j.molbiopara.2006.09.001 PMID: 17014918.
21. Roepe PD. PfCRT-mediated drug transport in malarial parasites. Biochemistry. 2011; 50(2):163–71.
doi: 10.1021/bi101638n PMID: 21142008.
Molecular Analysis of the Evolution of Fitness Cost-Neutral Mutant PfCRT
PLOS Pathogens | DOI:10.1371/journal.ppat.1005976 November 10, 2016 25 / 29
22. Callaghan PS, Hassett MR, Roepe PD. Functional comparison of 45 naturally occurring isoforms of
the Plasmodium falciparum chloroquine resistance transporter (PfCRT). Biochemistry. 2015; 54
(32):5083–94. doi: 10.1021/acs.biochem.5b00412 PMID: 26208441.
23. Summers RL, Dave A, Dolstra TJ, Bellanca S, Marchetti RV, et al. Diverse mutational pathways con-
verge on saturable chloroquine transport via the malaria parasite’s chloroquine resistance transporter.
Proc Natl Acad Sci U S A. 2014; 111(17):E1759–67. doi: 10.1073/pnas.1322965111 PMID: 24728833.
24. Richards SN, Nash MN, Baker ES, Webster MW, Lehane AM, et al. Molecular mechanisms for drug
hypersensitivity induced by the malaria parasite’s chloroquine resistance transporter. PLoS Pathog.
2016; 12(7):e1005725. doi: 10.1371/journal.ppat.1005725 PMID: 27441371.
25. Beshir K, Sutherland CJ, Merinopoulos I, Durrani N, Leslie T, et al. Amodiaquine resistance in Plasmo-
dium falciparum malaria in Afghanistan is associated with the pfcrt SVMNT allele at codons 72 to 76.
Antimicrob Agents Chemother. 2010; 54(9):3714–6. doi: 10.1128/AAC.00358-10 PMID: 20547800.
26. Eastman RT, Dharia NV, Winzeler EA, Fidock DA. Piperaquine resistance is associated with a copy
number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob
Agents Chemother. 2011; 55(8):3908–16. doi: 10.1128/AAC.01793-10 PMID: 21576453.
27. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, et al. Genetic architecture of artemisi-
nin-resistant Plasmodium falciparum. Nat Genet. 2015; 47(3):226–34. doi: 10.1038/ng.3189 PMID:
25599401.
28. Sisowath C, Petersen I, Veiga MI, Martensson A, Premji Z, et al. In vivo selection of Plasmodium falcip-
arum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-
lumefantrine in Africa. J Infect Dis. 2009; 199(5):750–7. doi: 10.1086/596738 PMID: 19210165.
29. Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, et al. Artesunate/amodiaquine versus artemether/
lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J Infect Dis.
2016; 213(7):1134–42. doi: 10.1093/infdis/jiv551 PMID: 26597254.
30. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, et al. Dihydroartemisinin-piperaquine resistance in
Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis.
2016; 16(3):357–65. doi: 10.1016/S1473-3099(15)00487-9 PMID: 26774243.
31. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, et al. Spread of artemisinin resistance in
Plasmodium falciparum malaria. N Engl J Med. 2014; 371(5):411–23. doi: 10.1056/NEJMoa1314981
PMID: 25075834.
32. Combrinck JM, Mabotha TE, Ncokazi KK, Ambele MA, Taylor D, et al. Insights into the role of heme in
the mechanism of action of antimalarials. ACS Chem Biol. 2013; 8(1):133–7. doi: 10.1021/cb300454t
PMID: 23043646.
33. Chugh M, Sundararaman V, Kumar S, Reddy VS, Siddiqui WA, et al. Protein complex directs hemoglo-
bin-to-hemozoin formation in Plasmodium falciparum. Proc Natl Acad Sci U S A. 2013; 110(14):5392–
7. doi: 10.1073/pnas.1218412110 PMID: 23471987.
34. Klonis N, Creek DJ, Tilley L. Iron and heme metabolism in Plasmodium falciparum and the mechanism
of action of artemisinins. Curr Opin Microbiol. 2013; 16(6):722–7. doi: 10.1016/j.mib.2013.07.005
PMID: 23932203.
35. Sigala PA, Goldberg DE. The peculiarities and paradoxes of Plasmodium heme metabolism. Annu
Rev Microbiol. 2014; 68:259–78. doi: 10.1146/annurev-micro-091313-103537 PMID: 25002093.
36. Lehane AM, McDevitt CA, Kirk K, Fidock DA. Degrees of chloroquine resistance in Plasmodium—is
the redox system involved? Int J Parasitol Drugs Drug Resist. 2012; 2:47–57. doi: 10.1016/j.ijpddr.
2011.11.001 PMID: 22773965.
37. Egan TJ, Combrinck JM, Egan J, Hearne GR, Marques HM, et al. Fate of haem iron in the malaria par-
asite Plasmodium falciparum. Biochem J. 2002; 365(Pt 2):343–7. doi: 10.1042/BJ20020793 PMID:
12033986.
38. Gorka AP, de Dios A, Roepe PD. Quinoline drug-heme interactions and implications for antimalarial
cytostatic versus cytocidal activities. J Med Chem. 2013; 56(13):5231–46. doi: 10.1021/jm400282d
PMID: 23586757.
39. Papakrivos J, Sa JM, Wellems TE. Functional characterization of the Plasmodium falciparum chloro-
quine-resistance transporter (PfCRT) in transformed Dictyostelium discoideum vesicles. PLoS One.
2012; 7(6):e39569. doi: 10.1371/journal.pone.0039569 PMID: 22724026.
40. Gligorijevic B, Bennett T, McAllister R, Urbach JS, Roepe PD. Spinning disk confocal microscopy of
live, intraerythrocytic malarial parasites. 2. Altered vacuolar volume regulation in drug resistant
malaria. Biochemistry. 2006; 45(41):12411–23. doi: 10.1021/bi0610348 PMID: 17029397.
41. Lewis IA, Wacker M, Olszewski KL, Cobbold SA, Baska KS, et al. Metabolic QTL analysis links chloro-
quine resistance in Plasmodium falciparum to impaired hemoglobin catabolism. PLoS Genet. 2014;
10(1):e1004085. doi: 10.1371/journal.pgen.1004085 PMID: 24391526.
Molecular Analysis of the Evolution of Fitness Cost-Neutral Mutant PfCRT
PLOS Pathogens | DOI:10.1371/journal.ppat.1005976 November 10, 2016 26 / 29
42. Petersen I, Gabryszewski SJ, Johnston GL, Dhingra SK, Ecker A, et al. Balancing drug resistance and
growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance trans-
porter. Mol Microbiol. 2015; 97(2):381–95. doi: 10.1111/mmi.13035 PMID: 25898991.
43. Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, et al. Return of widespread
chloroquine-sensitive Plasmodium falciparum to Malawi. J Infect Dis. 2014; 210(7):1110–4. doi: 10.
1093/infdis/jiu216 PMID: 24723474.
44. Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, et al. Seasonal carriage of pfcrt and pfmdr1 alleles
in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J Infect
Dis. 2007; 196(11):1613–9. doi: 10.1086/522154 PMID: 18008244.
45. Mharakurwa S, Sialumano M, Liu K, Scott A, Thuma P. Selection for chloroquine-sensitive Plasmo-
dium falciparum by wild Anopheles arabiensis in Southern Zambia. Malar J. 2013; 12(1):453. doi: 10.
1186/1475-2875-12-453 PMID: 24354640.
46. Rosenthal PJ. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol.
2013; 89(6):1025–38. doi: 10.1111/mmi.12349 PMID: 23899091.
47. Durrand V, Berry A, Sem R, Glaziou P, Beaudou J, et al. Variations in the sequence and expression of
the Plasmodium falciparum chloroquine resistance transporter (PfCRT) and their relationship to chlo-
roquine resistance in vitro. Mol Biochem Parasitol. 2004; 136(2):273–85. PMID: 15478806.
48. Straimer J, Lee MC, Lee AH, Zeitler B, Williams AE, et al. Site-specific genome editing in Plasmodium
falciparum using engineered zinc-finger nucleases. Nat Methods. 2012; 9(10):993–8. doi: 10.1038/
nmeth.2143 PMID: 22922501.
49. Su X, Kirkman LA, Fujioka H, Wellems TE. Complex polymorphisms in an approximately 330 kDa pro-
tein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell. 1997; 91
(5):593–603. PMID: 9393853.
50. Valderramos SG, Valderramos JC, Musset L, Purcell LA, Mercereau-Puijalon O, et al. Identification of
a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. PLoS Pathog.
2010; 6(5):e1000887. doi: 10.1371/journal.ppat.1000887 PMID: 20485514.
51. Johnson DJ, Fidock DA, Mungthin M, Lakshmanan V, Sidhu AB, et al. Evidence for a central role for
PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol Cell. 2004;
15(6):867–77. doi: 10.1016/j.molcel.2004.09.012 PMID: 15383277.
52. Lakshmanan V, Bray PG, Verdier-Pinard D, Johnson DJ, Horrocks P, et al. A critical role for PfCRT
K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 2005; 24
(13):2294–305. doi: 10.1038/sj.emboj.7600681 PMID: 15944738.
53. Sanchez CP, McLean JE, Rohrbach P, Fidock DA, Stein WD, et al. Evidence for a pfcrt-associated
chloroquine efflux system in the human malarial parasite Plasmodium falciparum. Biochemistry. 2005;
44(29):9862–70. doi: 10.1021/bi050061f PMID: 16026158.
54. Bray PG, Mungthin M, Hastings IM, Biagini GA, Saidu DK, et al. PfCRT and the trans-vacuolar proton
electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol Microbiol.
2006; 62(1):238–51. doi: 10.1111/j.1365-2958.2006.05368.x PMID: 16956382.
55. Cabrera M, Natarajan J, Paguio MF, Wolf C, Urbach JS, et al. Chloroquine transport in Plasmodium
falciparum. 1. Influx and efflux kinetics for live trophozoite parasites using a novel fluorescent chloro-
quine probe. Biochemistry. 2009; 48(40):9471–81. doi: 10.1021/bi901034r PMID: 19728740.
56. Lehane AM, Kirk K. Efflux of a range of antimalarial drugs and ’chloroquine resistance reversers’ from
the digestive vacuole in malaria parasites with mutant PfCRT. Mol Microbiol. 2010; 77(4):1039–51.
doi: 10.1111/j.1365-2958.2010.07272.x PMID: 20598081.
57. Patzewitz EM, Salcedo-Sora JE, Wong EH, Sethia S, Stocks PA, et al. Glutathione transport: a new
role for PfCRT in chloroquine resistance. Antioxid Redox Signal. 2013; 19(7):683–95. doi: 10.1089/
ars.2012.4625 PMID: 23256874.
58. Hrycyna CA, Summers RL, Lehane AM, Pires MM, Namanja H, et al. Quinine dimers are potent inhibi-
tors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-
resistant P. falciparum. ACS Chem Biol. 2014; 9(3):722–30. doi: 10.1021/cb4008953 PMID: 24369685.
59. Adjalley SH, Scanfeld D, Kozlowski E, Llinas M, Fidock DA. Genome-wide transcriptome profiling
reveals functional networks involving the Plasmodium falciparum drug resistance transporters PfCRT
and PfMDR1. BMC Genomics. 2015; 16(1):1090. doi: 10.1186/s12864-015-2320-8 PMID: 26689807.
60. Pelleau S, Moss EL, Dhingra SK, Volney B, Casteras J, et al. Adaptive evolution of malaria parasites in
French Guiana: Reversal of chloroquine resistance by acquisition of a mutation in pfcrt. Proc Natl Acad
Sci U S A. 2015; 112(37):11672–7. doi: 10.1073/pnas.1507142112 PMID: 26261345.
61. Pulcini S, Staines HM, Lee AH, Shafik SH, Bouyer G, et al. Mutations in the Plasmodium falciparum
chloroquine resistance transporter, PfCRT, enlarge the parasite’s food vacuole and alter drug sensitivi-
ties. Sci Rep. 2015; 5:14552. doi: 10.1038/srep14552 PMID: 26420308.
Molecular Analysis of the Evolution of Fitness Cost-Neutral Mutant PfCRT
PLOS Pathogens | DOI:10.1371/journal.ppat.1005976 November 10, 2016 27 / 29
62. Goswami D, Dhiman S, Rabha B, Kumar D, Baruah I, et al. PfCRT mutant haplotypes may not corre-
spond with chloroquine resistance. J Infect Dev Ctries. 2014; 8(6):768–73. doi: 10.3855/jidc.3398
PMID: 24916876.
63. Mehlotra RK, Fujioka H, Roepe PD, Janneh O, Ursos LM, et al. Evolution of a unique Plasmodium fal-
ciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New
Guinea and South America. Proc Natl Acad Sci U S A. 2001; 98(22):12689–94. doi: 10.1073/pnas.
221440898 PMID: 11675500.
64. Sa JM, Twu O, Hayton K, Reyes S, Fay MP, et al. Geographic patterns of Plasmodium falciparum drug
resistance distinguished by differential responses to amodiaquine and chloroquine. Proc Natl Acad Sci
U S A. 2009; 106(45):18883–9. doi: 10.1073/pnas.0911317106 PMID: 19884511.
65. Leang R, Taylor WR, Bouth DM, Song L, Tarning J, et al. Evidence of Plasmodium falciparum malaria
multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-pipera-
quine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015; 59(8):4719–
26. doi: 10.1128/AAC.00835-15 PMID: 26014949.
66. Saunders DL, Vanachayangkul P, Lon C, et al. Dihydroartemisinin-piperaquine failure in Cambodia. N
Engl J Med. 2014; 371(5):484–5. doi: 10.1056/NEJMc1403007 PMID: 25075853.
67. Waller KL, Muhle RA, Ursos LM, Horrocks P, Verdier-Pinard D, et al. Chloroquine resistance modu-
lated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter. J
Biol Chem. 2003; 278(35):33593–601. doi: 10.1074/jbc.M302215200 PMID: 12813054.
68. Hartl DL. What can we learn from fitness landscapes? Curr Opin Microbiol. 2014; 21:51–7. doi: 10.
1016/j.mib.2014.08.001 PMID: 25444121.
69. Baragana B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, et al. A novel multiple-stage antimalarial
agent that inhibits protein synthesis. Nature. 2015; 522(7556):315–20. doi: 10.1038/nature14451
PMID: 26085270.
70. Goldberg DE. Complex nature of malaria parasite hemoglobin degradation. Proc Natl Acad Sci U S A.
2013; 110(14):5283–4. doi: 10.1073/pnas.1303299110 PMID: 23513214.
71. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeo-
stasis. Nat Rev Mol Cell Biol. 2012; 13(4):251–62. doi: 10.1038/nrm3311 PMID: 22436748.
72. Sandlin RD, Fong KY, Wicht KJ, Carrell HM, Egan TJ, et al. Identification of beta-hematin inhibitors in
a high-throughput screening effort reveals scaffolds with in vitro antimalarial activity. Int J Parasitol
Drugs Drug Resist. 2014; 4(3):316–25. doi: 10.1016/j.ijpddr.2014.08.002 PMID: 25516843.
73. Combrinck JM, Fong KY, Gibhard L, Smith PJ, Wright DW, et al. Optimization of a multi-well colorimet-
ric assay to determine haem species in Plasmodium falciparum in the presence of anti-malarials.
Malar J. 2015; 14:253. doi: 10.1186/s12936-015-0729-9 PMID: 26099266.
74. Baro NK, Pooput C, Roepe PD. Analysis of chloroquine resistance transporter (CRT) isoforms and
orthologues in S. cerevisiae yeast. Biochemistry. 2011; 50(31):6701–10. doi: 10.1021/bi200922g
PMID: 21744797.
75. Baro NK, Callaghan PS, Roepe PD. Function of resistance conferring Plasmodium falciparum chloro-
quine resistance transporter isoforms. Biochemistry. 2013; 52(24):4242–9. doi: 10.1021/bi400557x
PMID: 23688277.
76. Bennett TN, Kosar AD, Ursos LM, Dzekunov S, Singh Sidhu AB, et al. Drug resistance-associated
PfCRT mutations confer decreased Plasmodium falciparum digestive vacuolar pH. Mol Biochem Para-
sitol. 2004; 133(1):99–114. PMID: 14668017.
77. Callaghan PS, Siriwardana A, Hassett MR, Roepe PD. Plasmodium falciparum chloroquine resistance
transporter (PfCRT) isoforms PH1 and PH2 perturb vacuolar physiology. Malar J. 2016; 15(1):186.
doi: 10.1186/s12936-016-1238-1 PMID: 27036417.
78. Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, et al. Clearance of drug-resistant para-
sites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003;
69(5):558–63. PMID: 14695097.
79. Pisciotta JM, Coppens I, Tripathi AK, Scholl PF, Shuman J, et al. The role of neutral lipid nanospheres
in Plasmodium falciparum haem crystallization. Biochem J. 2007; 402(1):197–204. doi: 10.1042/
BJ20060986 PMID: 17044814.
80. Famin O, Ginsburg H. Differential effects of 4-aminoquinoline-containing antimalarial drugs on hemo-
globin digestion in Plasmodium falciparum-infected erythrocytes. Biochem Pharmacol. 2002; 63
(3):393–8. PMID: 11853690.
81. Roberts L, Egan TJ, Joiner KA, Hoppe HC. Differential effects of quinoline antimalarials on endocytosis
in Plasmodium falciparum. Antimicrob Agents Chemother. 2008; 52(5):1840–2. doi: 10.1128/AAC.
01478-07 PMID: 18316523.
Molecular Analysis of the Evolution of Fitness Cost-Neutral Mutant PfCRT
PLOS Pathogens | DOI:10.1371/journal.ppat.1005976 November 10, 2016 28 / 29
82. Schmitt TH, Frezzatti WA Jr., Schreier S. Hemin-induced lipid membrane disorder and increased per-
meability: a molecular model for the mechanism of cell lysis. Arch Biochem Biophys. 1993; 307(1):96–
103. doi: 10.1006/abbi.1993.1566 PMID: 8239671.
83. Ginsburg H, Famin O, Zhang J, Krugliak M. Inhibition of glutathione-dependent degradation of heme
by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem
Pharmacol. 1998; 56(10):1305–13. PMID: 9825729.
84. Elliott DA, McIntosh MT, Hosgood HD 3rd, Chen S, Zhang G, et al. Four distinct pathways of hemoglo-
bin uptake in the malaria parasite Plasmodium falciparum. Proc Natl Acad Sci U S A. 2008; 105
(7):2463–8. doi: 10.1073/pnas.0711067105 PMID: 18263733.
85. Ogbunugafor CB, Hartl D. A pivot mutation impedes reverse evolution across an adaptive landscape
for drug resistance in Plasmodium vivax. Malar J. 2016; 15(1):40. doi: 10.1186/s12936-016-1090-3
PMID: 26809718.
86. Ogbunugafor CB, Wylie CS, Diakite I, Weinreich DM, Hartl DL. Adaptive landscape by environment
interactions dictate evolutionary dynamics in models of drug resistance. PLoS Comput Biol. 2016; 12
(1):e1004710. doi: 10.1371/journal.pcbi.1004710 PMID: 26808374.
87. Malaria GENPfCP. Genomic epidemiology of artemisinin resistant malaria. Elife. 2016; 5 doi: 10.7554/
eLife.08714 PMID: 26943619.
88. Chen N, Kyle DE, Pasay C, Fowler EV, Baker J, et al. pfcrt Allelic types with two novel amino acid
mutations in chloroquine-resistant Plasmodium falciparum isolates from the Philippines. Antimicrob
Agents Chemother. 2003; 47(11):3500–5. PMID: 14576108. doi: 10.1128/AAC.47.11.3500-3505.
2003
89. Yang Z, Zhang Z, Sun X, Wan W, Cui L, et al. Molecular analysis of chloroquine resistance in Plasmo-
dium falciparum in Yunnan Province, China. Trop Med Int Health. 2007; 12(9):1051–60. doi: 10.1111/
j.1365-3156.2007.01882.x PMID: 17875016.
90. Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across
diverse targets and organisms. Nat Rev Genet. 2015; 16(8):459–71. doi: 10.1038/nrg3922 PMID:
26149714.
91. Wellems TE, Walker-Jonah A, Panton LJ. Genetic mapping of the chloroquine-resistance locus on
Plasmodium falciparum chromosome 7. Proc Natl Acad Sci U S A. 1991; 88(8):3382–6. PMID:
1673031.
92. Rohrbach P, Sanchez CP, Hayton K, Friedrich O, Patel J, et al. Genetic linkage of pfmdr1 with food
vacuolar solute import in Plasmodium falciparum. EMBO J. 2006; 25(13):3000–11. doi: 10.1038/sj.
emboj.7601203 PMID: 16794577.
93. Jiang H, Patel JJ, Yi M, Mu J, Ding J, et al. Genome-wide compensatory changes accompany drug-
selected mutations in the Plasmodium falciparum crt gene. PLoS One. 2008; 3(6):e2484. doi: 10.
1371/journal.pone.0002484 PMID: 18575593.
94. Lee MC, Fidock DA. CRISPR-mediated genome editing of Plasmodium falciparum malaria parasites.
Genome Med. 2014; 6(8):63. doi: 10.1186/s13073-014-0063-9 PMID: 25473431.
95. Fidock DA, Nomura T, Wellems TE. Cycloguanil and its parent compound proguanil demonstrate dis-
tinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate
reductase. Mol Pharmacol. 1998; 54(6):1140–7. PMID: 9855645.
96. Makler MT, Ries JM, Williams JA, Bancroft JE, Piper RC, et al. Parasite lactate dehydrogenase as an
assay for Plasmodium falciparum drug sensitivity. Am J Trop Med Hyg. 1993; 48(6):739–41. PMID:
8333566.
Molecular Analysis of the Evolution of Fitness Cost-Neutral Mutant PfCRT
PLOS Pathogens | DOI:10.1371/journal.ppat.1005976 November 10, 2016 29 / 29
